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jelena.srbljanovic@imi.bg.ac.rs (J.S.); olgicadj@imi.bg.ac.rs (O.DjDj.) 
4 Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United 
States; richard.j.sciotti.civ@mail.mil (R.S.) 
* Correspondence: bsolaja@chem.bg.ac.rs; Tel.: +381-11-263-86-06 
 
 
 
 
 
 
 
 
 
 
 
S2 
 
Table of contents 
 
Chemistry                                                                                                                              S3 
In vitro antiplasmodial activity                                                                                       S33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S3 
 
Chemistry 
 
Compounds were analyzed for purity (HPLC) using a Agilent 1200 HPLC system equipped with 
Quat Pump (G1311B), Injector (G1329B) 1260 ALS, TCC 1260 ( G1316A) and Detector 1260 DAD VL+ 
(G1315C). HPLC analysis for each compound was performed in two diverse systems.  All compounds 
were ≥95% pure.  
Method A: Zorbax Eclipse Plus C18 4.6 × 150 mm, 1.8µ, S.N. USWKY01594 was used as the stationary 
phase. Eluent was made of the following solvents: 0.2% formic acid in water (A) and methanol (B). The 
analysis were performed at the UV max of the compounds (at 330 nm for compounds 8, 9, 12, 13, 23, 24, 
25, 26, 27, 28, 29, 30, 31, 32, 41, 44 and 52) to maximize selectivity. Compounds were dissolved in 
methanol, final concentrations were ~1 mg/mL. Flow rate was 0.5 mL/min.  
Compounds 8, 9, 13, 25, and 26 were eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95%A→ 
5%A, 6-11 min 5%A, 11-14 min 5%A→ 95%A. 
Compounds 12, 27, 28, 29, 30, 31 and 32 were eluted using gradient protocol: 0-1 min 95%A, 1-6 min 
95%A→ 5%A, 6-11 min 5%A, 11-14 min 5%A→ 95 %A, 14-15 min 95%A. 
Compound 23 was eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95%A→ 5%A, 6-11 min 5%A, 
11-14 min 5%A→ 95 %A, 14-18 min 95%A. 
Compound 24 was eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95%A→ 5%A, 6-11 min 5%A, 
11-14 min 5%A→ 95%A, 14-16 min 95%A. 
Compound 41 was eluted using gradient protocol: 0-1 min 95%A, 1-2 min 95%A→ 5%A, 2-10 min 5%A, 
10-11 min 5%A→ 95%A, 11-13 min 95%A. 
Compound 44 was eluted using gradient protocol: 0-1.5 min 95%A, 1.5-5 min 95%A→ 5%A, 5-16 min 
5%A, 16-18 min 5%A→ 95%A, 18-19 min 95% A. 
Compound 52 was eluted using gradient protocol: 0-2 min 95%A, 2-6 min 95%A→ 5%A, 6-17 min 5%A, 
17-19 min 5%A→ 95%A, 19-21 min 95% A. 
Method B: Zorbax Eclipse Plus C18 4.6 x 150 mm, 1.8µ, S.N. USWKY01594 was used as the stationary 
phase. Eluent was made of the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The 
analysis were performed at the UV max of the compounds (at 330 nm for compounds 8, 9, 12, 13, 24, 26, 
27, 31, 32, 41, 44, 52 and at 254 nm for compounds 23, 25, 28, 29 and 30) to maximize selectivity. 
Compounds were dissolved in methanol, final concentrations were ~1 mg/mL. Flow rate was 0.5 mL/min.  
Compounds 8, 9, 13, 23, 24, 25 and 26 were eluted using gradient protocol: 0-1 min 95%A, 1-6 min 
95%A→ 5%A, 6-11 min 5%A, 11-14 min 5%A→ 95 %A. 
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Compounds 12, 27, 28, 29, 30, 31 and 32 were eluted using gradient protocol: 0-1 min 95%A, 1-6 min 
95%A→ 5%A, 6-11 min 5%A, 11-14 min 5%A→ 95 %A, 14-15 min 95%A. 
Compound 41 was eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 5%A, 1.5-9 min 5%A, 
9-10 min 5%A→ 95%A, 10-12 min 95%A. 
Compound 44 was eluted using gradient protocol: 0-1.5 min 95%A, 1.5-5 min 95%A→ 5%A, 5-16 min 
5%A, 16-18 min 5%A→ 95%A, 18-19 min 95% A. 
Compound 52 was eluted using gradient protocol: 0-1.5 min 95%A, 1.5-5 min 95%A→ 5%A, 5-14 min 
5%A, 14-15 min 5%A→ 95%A, 15-16 min 95% A. 
Method C: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the stationary 
phase. Eluent was made of the following solvents: 0.2% formic acid in water (A) and methanol (B). The 
analysis were performed at the UV max of the compounds (at 330 nm for compounds  38, 39, 40 and 43 to 
maximize selectivity. Compounds were dissolved in methanol, final concentrations were ~1 mg/mL. Flow 
rate was 0.2 mL/min.  
Compounds 38, 39 and 40 were eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 5%A, 
1.5-8 min 5%A, 8-10 min 5%A→ 95%A, 10-12 min 95%A. 
Compound 43 was eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 5%A, 1.5-9 min 5%A, 
9-10 min 5%A→ 95%A, 10-12 min 95%A. 
Method D: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the stationary 
phase. Eluent was made of the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The 
analysis were performed at the UV max of the compounds (at 330 nm for compounds 27, 38, 39, 40 and 
42) to maximize selectivity. Compounds were dissolved in methanol, final concentrations were ~1 
mg/mL. Flow rate was 0.2 mL/min.  
Compounds 38, 39 and 40 were eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 5%A, 
1.5-8 min 5%A, 8-10 min 5%A→ 95%A, 10-12 min 95%A.  
Compound 42 was eluted using gradient protocol: 0-1 min 95%A, 1-8 min 95%A→ 5%A, 8-10 min 5%A, 
10-12 min 5%A→ 95%A, 12-14 95%A. 
Compound 43 was eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 5%A, 1.5-8 min 5%A, 
8-10 min 5%A→ 95%A.  
Method E: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the stationary 
phase. Eluent was made of the following solvents: water (A) and acetonitrile (B). The analysis were 
performed at the UV max of the compound (at 330 nm for compound 37)to maximize selectivity. The 
compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.2 mL/min.  
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Compound 37 was eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 5%A, 1.5-9 min 5%A, 
9-10 min 5%A→ 95%A, 10-12 min 95%A. 
Method F: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the stationary 
phase. Eluent was made of the following solvents: water (A) and methanol (B). The analysis were 
performed at the UV max of the compounds (at 330 nm for compound 37) to maximize selectivity. The 
compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.2 mL/min.  
Compound 37 was eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 5%A, 1.5-9 min 5%A, 
9-10 min 5%A→ 95%A, 10-12 min 95%A. 
Method G: Zorbax Eclipse Plus C18 4.6 x 150 mm, 1.8µ, S.N. USWKY01594 was used as the stationary 
phase. Eluent was made of the following solvents: water (A) and acetonitrile (B). The analysis were 
performed at the UV max of the compounds (at 330 nm for compound 42) to maximize selectivity. The 
compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.5 mL/min.  
Compound 42 was eluted using gradient protocol: 0-1.5 min 95%A, 1.5-5 min 95%A→ 5%A, 5-13 min 
5%A, 13-14 min 5%A→ 95%A, 14-15 min 95% A. 
Method H: Poroshell 120 EC-C18, 4.6 x 50mm, 2.7µ, S.N. USCFU07797 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). Analyses 
were performed at the UV max of the compounds (330 nm for compound 46) to maximize selectivity. The 
compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.5 mL/min.  
Compound 46 was eluted using gradient protocol: 0-1 min 95%A, 1-3 min 95%A→ 5%A, 3-8 min 5%A, 8-
10 min 5%A→ 95%A, 10-11 min 95%A. 
Method I: Poroshell 120 EC-C18, 4.6 x 50mm, 2.7µ, S.N. USCFU07797 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis 
were performed at the UV max of the compounds (330 nm for compound 46) to maximize selectivity.  
The compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.5 ml/min. 
Compound 46 was eluted using gradient protocol: 0-1 min 95%A, 1-3 min 95%A→ 5%A, 3-8 min 5%A, 8-
10 min 5%A→ 95%A, 10-11 min 95%A. 
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N-(1-benzothiophen-2-ylmethyl)-N'-(quinolin-4-yl)propane-1,3-diamine (8).  
Compound 8 was prepared by method A, using 1-
benzothiophene-2-carbaldehyde (94.0 mg, 0.580 mmol), AQ7 
[1] (175 mg, 0.870 mmol), glac. AcOH (50 μL, 0.8 mmol) and 
MeOH/CH2Cl2 (24 mL, 2:1, v/v). The product was purified 
using column chromatography (dry-flash, SiO2, eluent EtOAc/hexane gradient 1/9 → EtOAc, 
EtOAc/MeOH gradient 95/5 → 1/1, flash, Biotage SP1, NH column, eluent EtOAc/hexane gradient 8/2 → 
EtOAc, EtOAc/MeOH gradient 95/5 → MeOH and flash, Biotage SP1, SiO2 column, eluent 
EtOAc/MeOH+NH3 (9/1) gradient 95/5 → 1/1). Final product 8 was obtained as a pale yellow oil (119 mg, 
59%). IR (ATR): 3262w, 3059w, 2928w, 2838w, 1617w, 1585s, 1542m, 1458w, 1438w, 1396w, 1372w, 1339w, 
1284w, 1243w, 1131w, 862w, 810w, 765m, 728w cm-1.  1H NMR (500MHz, CDCl3, δ): 8.55-8.48 (m, H-C(2')), 
7.98-7.91 (m, H-C(8')), 7.79 (d, J = 7.8, H-C(5')), 7.73-7.68 (m, H-C(7) and H-C(4)), 7.57-7.53 (m, H-C(7')), 
7.36-7.28 (m, H-C(5) and H-C(6)), 7.20-7.15 (m, H-C(6') and H-C(3)), 6.96 (bs, H-N exchangeable with 
D2O),  6.35-6.32 (m, H-C(3')),  4.12 (s, 2H, ArCH2-), 3.45-3.39 (m, 2H, ArNHCH2-), 2.96-2.92 (m, 2H, 
ArCH2NHCH2-), 2.15 (bs, H-N exchangeable with D2O), 1.95-1.88 (m, 2H, ArNHCH2CH2-). 13C NMR (50 
MHz, CDCl3, δ): 150.77, 150.36, 144.26, 139.65, 139.56, 129.25, 128.94, 124.32, 124.10, 123.19, 122.37, 121.84, 
120.40, 118.91, 98.06, 49.27, 48.27, 43.12, 27.62. HRMS: m/z 348.15289 corresponds to molecular formula 
C21H21N3SH+ (error in ppm 0.07). HPLC purity (λ = 330 nm): method A: RT 10.408, area 96.80%; method B: 
RT 8.140, area 96.44%. 
N-(1-benzothiophen-2-ylmethyl)-N'-(quinolin-4-yl)butane-1,4-diamine (9). 
NH
NH
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Compound 9 was prepared by method A, using 1-
benzothiophene-2-carbaldehyde (120 mg, 0.74 mmol), AQ8 
[1] (240 mg, 1.1 mmol), glac. AcOH (63 μL, 1.1 mmol) and 
MeOH/CH2Cl2 (24 mL, 2:1, v/v). The product was purified 
using column chromatography (dry-flash, SiO2, eluent EtOAc/hexane gradient 1/9 → EtOAc, 
EtOAc/MeOH gradient 95/5 → 1/9). Final product 9 was obtained as a pale yellow oil (160 mg, 58%). IR 
(ATR): 3649w, 3626w, 3436w, 3250m, 3117w, 3060m, 2929m, 2855m, 1617w, 1582s, 1541m, 1457m, 1438m, 
1396w, 1374w, 1342m, 1280w, 1260w, 1225w, 1129w, 1065w, 1016w, 972w, 861w, 811w, 764m, 744m, 
703w, 589w, 558w, 476w cm-1.  1H NMR (500MHz, CDCl3, δ): 8.52 (d, J = 5.2, H-C(2')), 7.96 (d, J = 8.2, H-
C(8’)), 7.79-7.73 (m, H-C(4) and H-C(7)), 7.68 (d, J = 7.6, H-C(5’)), 7.60-7.56 (m, H-C(7’)), 7.35-7.25 (m, H-
C(5) and H-C(6) and H-C(6’)), 7.13 (s, H-C(3)), 6.37 (d, J = 5.2, H-C(3')),  5.62-5.55 (m, H-N exchangeable 
with D2O), 4.08 (s, 2H, ArCH2-), 3.34-3.27 (m, 2H, ArNHCH2-), 2.75 (t, J = 6.8, 2H, ArCH2NHCH2-), 2.05-
1.80 (m, 3H, ArNHCH2CH2- and H-N exchangeable with D2O), 1.68 (quin, J = 6.8, 2H, ArNHCH2CH2CH2-
). 13C NMR (125 MHz, CDCl3, δ): 150.98, 149.78, 148.35, 145.07, 139.70, 139.53, 129.77, 128.86, 124.40, 
124.17, 123.88, 123.08, 122.32, 121.27, 119.51, 118.76, 98.60, 49.07, 48.36, 43.09, 27.60, 26.30. HRMS: m/z 
362.16771 corresponds to molecular formula C22H23N3SH+ (error in ppm -2.30). HPLC purity (λ = 330 nm): 
method A: RT 8.370, area 96.73%; method B: RT 8.293, area 97.83%. 
N-[(6-fluoro-1-benzothiophen-3-yl)methyl]-N'-(quinolin-4-yl)propane-1,3-diamine (12). 
Compound 12 was prepared by method A, using aldehyde 
11 (164.3 mg, 0.9117 mmol), AQ7 [1] (275.3 mg, 1.368 mmol), 
glac. AcOH (78 μL, 1.4 mmol) and MeOH/CH2Cl2 (24 mL, 
2:1, v/v). The product was purified using column 
chromatography (dry-flash, SiO2, eluent EtOAc/hexane gradient 1/9 → EtOAc, EtOAc/MeOH gradient 
95/5 → 4/6, flash, Biotage SP1, NH column, eluent EtOAc/hexane gradient 8/2 → EtOAc, EtOAc/MeOH 
gradient 95/5 → MeOH and flash, Biotage SP1, SiO2 column, eluent EtOAc/MeOH+NH3 (9/1) gradient 
95/5 → 3/7). Final product 12 was obtained as a colorless oil (165 mg, 50%). IR (ATR): 3252m, 3072m, 
2925m, 2850m, 2359w, 1583s, 1539m, 1466m, 1398w, 1372w, 1338w, 1283w, 1252w, 1210w, 1132w, 1051w, 
895w, 851w, 811w, 765w, 736w cm-1.  1H NMR (500MHz, CDCl3, δ): 8.52-8.49 (m, H-C(2')), 7.93 (d, J = 8.6, 
H-C(8')), 7.76-7.71 (m, H-C(4)), 7.58-7.48 (m, H-C(7)) and H-C(7') and H-C(5’)),  7.29 (s, H-C(2)), 7.15-7.10 
(m, H-C(6’)), 7.08-6.99 (m, H-C(5) and H-N exchangeable with D2O), 6.34-6.31 (m, H-C(3’)), 4.07 (s, 2H, 
ArCH2-), 3.45-3.39 (m, 2H, ArNHCH2-), 3.04-2.98 (m, 2H, ArCH2NHCH2-), 2.10-1.85 (m, 3H, 
ArCH2NHCH2CH2- and H-N exchangeable with D2O). 13C NMR (125 MHz, CDCl3, δ): 160.64 (d, J = 243.2), 
NH
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150.82, 150.30, 148.09, 141.56 (d,  J = 9.6), 134.75, 134.20, 129.41, 128.88, 124.24, 122.89 (d, J = 3.5), 122.54 (d, J 
= 8.8), 120.06, 118.87, 113.20 (d, J = 24.5), 108.97 (d, J = 25.4), 98.10, 49.17, 47.75, 43.49, 27.74. HRMS: m/z 
366.14294 corresponds to molecular formula C21H20FN3SH+ (error in ppm -1.45). HPLC purity (λ = 330 
nm): method A: RT 8.353, area 98.30%; method B: RT 7.413, area 95.19%. 
N-[(5-fluoro-1-benzothiophen-3-yl)methyl]-N'-(quinolin-4-yl)butane-1,4-diamine (13). 
Compound 13 was prepared by method A, using aldehyde 10 
(90.0 mg, 0.499 mmol), AQ8 [1] (161.3 mg, 0.7492 mmol), glac. 
AcOH (43 μL, 0.75 mmol) and MeOH/CH2Cl2 (24 mL, 2:1, v/v). 
The product was purified using column chromatography (dry-
flash, SiO2, eluent EtOAc/hexane gradient 1/9 → EtOAc, EtOAc/MeOH gradient 95/5 → 8/2 and flash, 
Biotage SP1, NH column, eluent EtOAc/hexane gradient 8/2 → EtOAc, EtOAc/MeOH gradient 95/5 → 
MeOH). Final product 13 was obtained as pale yellow oil (112 mg, 59%). IR (ATR): 3649w, 3566w, 3255m, 
3074m, 2933m, 2858m, 1582s, 1541m, 1438m, 1396w, 1374w, 1342w, 1249w, 1198w, 1130w, 1082w, 1035w, 
914w, 855w, 808w, 765w, 736w, 647w cm-1.  1H NMR (500MHz, CDCl3, δ): 8.53 (d, J = 5.2, H-C(2')), 7.98-
7.93 (m, H-C(8’)), 7.76 (dd, J1 = 4.8, J2 = 8.7, H-C(7)), 7.70 (d, J = 8.2, H-C(5’)), 7.60-7.55 (m, H-C(7’)), 7.52-
7.47 (m, H-C(4)), 7.37 (s, H-C(3)), 7.30-7.25 (m, H-C(6’)), 7.13-7.06 (m, H-C(6)), 6.37 (d, J = 5.2, H-C(3')), 5.55 
(bs, H-N exchangeable with D2O), 4.01-3.97 (m, 2H, ArCH2-), 3.33-3.27 (m, 2H, ArNHCH2-),  2.78 (t, J = 6.9, 
2H, ArCH2NHCH2-), 1.89-1.81 (quin, J = 6.9, 2H, ArNHCH2CH2-), 1.80-1.66 (m, 3H, H-N exchangeable 
with D2O and ArNHCH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 160.70 (d, J = 240.1), 150.97, 149.75, 
148.33, 139.49 (d, J = 9.0),  135.94, 134.89 (d, J = 4.5), 129.78, 128.87, 125.33, 124.38, 123.92 (d, J = 9.0), 119.40, 
118.74, 113.20 (d, J = 25.3), 107.50 (d, J = 23.5), 98.60, 49.02, 47.67, 43.07, 27.68, 26.42. HRMS: m/z  190.58320 
corresponds to molecular formula C22H22N3SFH22+ (error in ppm 0.00) m/z 380.15904 corresponds to 
molecular formula C22H22N3SFH+ (error in ppm -0.21). HPLC purity (λ = 330 nm): method A: RT 10.817, 
area 98.73%; method B: RT 8.234, area 97.72%. 
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tert-butyl [4-(quinolin-4-ylamino)pentyl]carbamate (S2). 
4-chloroquinoline (216 mg, 1.32 mmol) and amine tert-butyl (4-
aminopentyl)carbamate S1 [1] (401 mg, 1.98 mmol) were heated at 120-130 C 
for 8 h with continued stirring as previously described in literature [2]. The 
reaction mixture was cooled to r.t. and taken up in CH2Cl2. The organic layer 
was washed with NaHCO3, wather and brine. The organic layer was dried over anhydrous Na2SO4 and 
solvent was evaporated under reduced pressure. The product S2 was purified using column 
chromatography (dry-flash, SiO2, eluent hexane/EtOAc gradient 1/1 → EtOAc, EtOAc/MeOH gradient 9/1 
→ 7/3 and flash, Biotage SP, NH column, 25+M, eluent hexane, hexane/EtOAc gradient 7/3 → EtOAc, 
EtOAc/MeOH → MeOH). Final product S2 was obtained as a yellow oil (230.5 mg, 53%). IR (ATR): 
3430w, 3343m, 3237m, 3116w, 3059w, 2974m, 2933m, 2870w, 1691s, 1618w, 1580s, 1537s, 1453m, 1394m, 
1367m, 1343m, 1258m, 1171m, 1045w, 1024w, 976w, 870w, 810w, 765m, 738m, 703w cm-1. 1H NMR (500 
MHz, CDCl3, δ): 8.53 (d, J = 5.4, H-C(2)), 7.99-7.95 (m, H-C(8)), 7.80-7.74 (m, H-C(5)), 7.64-7.60 (m, H-C(7)), 
7.44-7.39 (m, H-C(6)), 6.42 (d, J = 5.4, H-C(3)), 5.04-4.94 (m, NH), 4.61 (bs, NH), 3.80-3.70 (m, 1H, 
ArNHCH-), 3.25-3.10 (m, 2H, ArNHCH(CH3)CH2CH2CH2-), 1.75-1.55 (m, 4H, ArNHCH(CH3)CH2- and 
ArNHCH(CH3)CH2CH2-), 1.44 (s, 9H, -NHCOOC(CH3)3), 1.32 (d, J = 6.2, 3H, ArNHCH(CH3)-). 13C NMR 
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(125 MHz, CDCl3, δ): 156.11, 151.00, 148.76, 148.64, 129.99, 128.91, 124.46, 119.29, 118.76, 98.88, 79.30, 48.12, 
40.33, 33.52, 28.38, 27.03, 20.46. HRMS: m/z 330.21811 corresponds to molecular formula C19H27N3O2H+ 
(error in ppm 1.54). 
N4-(quinolin-4-yl)pentane-1,4-diamine (S3). 
A solution of compound S2 (210 mg, 0.64 mmol) in TFA/CH2Cl2 (5.5 mL, 1:10, 
v/v), was stirred at r.t. for 6 h. Solvents were evaporated under reduced pressure 
and the residue was treated with CH2Cl2/2.5M NaOH. The organic layer was 
dried over MgSO4, and the solvent was evaporated under reduced pressure. Final 
product S3 was obtained as a yellow oil (130 mg, 92%). IR (ATR): 3293m, 2972m, 2933m, 2872w, 1583s, 
1547m, 1503w, 1447w, 1397w, 1373w, 1342w, 1282w, 1257w, 1226w, 1148w, 917w, 890w, 809w, 769m cm-1. 
1H NMR (500 MHz, CD3OD, δ): 8.32 (d, J = 5.5, H-C(2)), 8.17-8.13 (m, H-C(8)), 7.80-7.76 (m, H-C(5)), 7.63-
7.57 (m, H-C(7)), 7.43-7.38 (m, H-C(6)), 6.50 (d, J = 6.0, H-C(3)), 3.82-3.74 (m, 1H, ArNHCH-), 2.65 (t, 2H, J 
= 7.0, ArCH(CH3)CH2CH2CH2-), 1.80-1.70 (m, 1H, ArNHCH(CH3)CH2-), 1.70-1.50 (m, 3H, 
ArNHCH(CH3)CH2- and ArNHCH(CH3)CH2CH2-), 1.31 (d, 3H, J = 6.4, CH3). 13C NMR (125 MHz, CD3OD, 
δ): 152.02, 151.25, 149.12, 130.39, 128.82, 125.43, 122.28, 120.33, 99.35, 49.42, 42.51, 34.67, 30.66, 20.43. 
HRMS: m/z 115.58609 corresponds to molecular formula C14H19N3H22+ (error in ppm -1.16). 
3-Bromo-5-fluoro-1-benzothiophene (17). 
Compound 17 was prepared by method B, using 5-fluoro-1-benzothiophene [1] (250 
mg, 1.6 mmol), Br2 (91 μL, 1.8 mmol) and CH2Cl2 (6.3 mL + 6.3 mL). The product was 
purified using column chromatography (dry-flash, SiO2, eluent hexane). Final product 
17 was obtained as colorless crystals (320 mg, 84%). M.p. = 70 – 73 °C. IR (ATR): 3964w, 3856w, 3818w, 
3795w, 3739w, 3641w, 3145w, 3099s, 3072m, 3021w, 2925w, 2889w, 2732w, 2684w, 2623w, 2561w, 2423w, 
2378w, 2264w, 2214w, 2162w, 2103w, 2055w, 1945w, 1880w, 1834w, 1712w, 1665w, 1602s, 1564w, 1538w, 
1494m, 1425s, 1326w, 1293m, 1244m, 1188s, 1126m, 1064w,  971m, 857s, 807w, 761w, 716w, 642w, 614w 
cm-1. 1H NMR (500MHz, CDCl3, δ): 7.78 (dd, J1 = 4.7, J2 = 8.8, H-C(7)), 7.53-7.48 (m, H-C(4) and H-C (2)),  
7.19-7.14 (m, H-C(6)). 13C NMR (125 MHz, CDCl3, δ): 161.36 (d, J = 241.2), 138.92 (d, J = 9.9), 133.92, 125.89, 
124.01 (d, J = 9.5), 114.36 (d, J = 25.3), 108.87 (d, J = 24.4), 107.02 (d, J = 4.5). GC/MS (m/z, %): 231.9 ([M+], 
100), 229.9 (99), 151.0 (22), 107.0 (58).  
3-Bromo-1-benzothiophene-5-carbonitrile (18). 
Compound 18 was prepared by method B, using 1-benzothiophene-5-carbonitrile [1] 
(100.0 mg, 0.6281 mmol), Br2 (35 μL, 0.69 mmol) and DCE (2.5 mL + 2.5 mL). The 
product was purified using column chromatography (dry-flash, SiO2, eluent hexane, 
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hexane/EtOAc gradient 97/3 → 9/1). Final product 18 was obtained as colorless crystals (130 mg, 87%). 
M.p. = 144 – 147 °C. IR (ATR): 3116s, 3074m, 2224s, 1768m, 1597m, 1572m, 1497m, 1431s, 1322m, 1293m, 
1253m, 1154w, 1128w, 1058m, 966w, 887m, 808m cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.16-8.14 (m, H-
C(7)), 7.93 (d, J = 8.2, H-C(4)), 7.64-7.61 (m, H-C(6)), 7.60 (s, H-C(2)). 13C NMR (125 MHz, CDCl3, δ): 142.68, 
137.68, 127.76, 127.20, 126.11, 123.78, 118.82, 109.03, 107.72. GC/MS (m/z, %): 239.8 ([M+], 100). 
3-Bromo-1-benzothiophene-6-carbonitrile (19). 
Compound 19 was prepared by method B, using compound 1-benzothiophene-6-
carbonitrile [1] (1.05 g, 6.60 mmol), Br2 (0.37 mL, 7.2 mmol) and DCE (26.3 mL + 26.3 
mL). The product was purified using column chromatography (dry-flash, SiO2, eluent 
hexane, hexane/EtOAc 97/3 → EtOAc). Final product 19 was obtained as colorless 
crystals (320 mg, 84%). M.p. = 140 – 144 °C (EtOAc). IR (ATR): 3950w, 3858w, 3821w, 3422m, 3145m, 
3096s, 3070s, 3034m, 2979m, 2935m, 2873w, 2852m, 2805w, 2718w, 2659m, 2629w, 2582w, 2528w, 2492w, 
2225s, 2176m, 2048w, 1903w, 1788m, 1770m, 1640m, 1598w, 1548m, 1513m, 1484w, 1455m, 1413s, 1392m, 
1350w, 1322s, 1258s, 1195s, 1164m, 1135m, 1058w, 937s, 894m, 816s, 769s, 709m, 605m cm-1. 1H NMR (500 
MHz, CDCl3, δ): 8.19-8.18 (m, H-C(7)), 7.93-7.90 (m, H-C(4)), 7.71-7.68 (m, H-C(2) and H-C(5)). 13C NMR 
(125 MHz, CDCl3, δ): 140.35; 138.54; 128.16; 127.63; 127.38; 123.92; 118.68; 108.91; 108.04. GC/MS (m/z, %): 
238.9 ([M+], 100); 158.0 (16); 114.0 (36). 
4-(5-Fluoro-1-benzothiophen-3-yl)benzaldehyde (20). 
Compound 20 was prepared by method C, using compound 17 (241 mg, 1.04 
mmol), 4-formylphenylboronic acid (195 mg, 1.30 mmol), Pd(OAc)2 (11.6 mg, 
0.0519 mmol), SPhos (85.3 mg, 0.208 mmol), 2M Na2CO3 (1.6 mL), DME (2 mL 
+ 2 mL) and EtOH (2 mL). The product was purified using column 
chromatography (dry-flash, SiO2, eluent hexane → hexane/EtOAc = 9/1). Final product 20 was obtained as 
white crystals (235 mg, 88%). M.p. = 125 – 127 °C. IR (ATR): 3094w, 2831w, 2736w, 1979w, 1702s, 1606s, 
1568w, 1493w, 1439m, 1388w, 1306w, 1282w, 1255w, 1208m, 1171w, 1117w, 885w, 860w, 836w, 816w, 
789w cm-1. 1H NMR (500MHz, CDCl3, δ): 10.08 (s, CHO), 8.03-7.99 (m, 2H-Ar), 7.85 (dd, J1 = 4.9, J2 = 8.8, H-
C(7)), 7.75-7.71 (m, 2H-Ar), 7.59 (s, H-C(2)), 7.58-7.54 (m, H-C(4)), 7.21-7.15 (m, H-C(6)). 13C NMR (125 
MHz, CDCl3, δ): 191.69, 161.26 (d, J = 241.0), 141.59, 138.50, 136.56 (d, J = 3.8), 136.09, 135.56, 130.33, 128.97, 
127.41, 124.20 (d, J = 9.9), 113.8 (d, J = 25.3), 108.33 (d, J = 23.5). GC/MS (m/z, %): 256.0 ([M+], 100), 226.0 
(35), 183.0 (31).  
3-(4-Formylphenyl)-1-benzothiophene-5-carbonitrile (21). 
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Compound 21 was prepared by method C, using compound 18 (300.0 mg, 
1.260 mmol), 4-formylphenylboronic acid (236.2 mg, 1.575 mmol), Pd(OAc)2 
(14.1 mg, 0.0628 mmol), SPhos (103.4 mg, 0.2519 mmol), 2 M Na2CO3 (2.4 
mL), DME (3.6 mL + 3.6 mL) and EtOH (3.6 mL). The product was purified 
using column chromatography (dry-flash, SiO2, eluent hexane/CH2Cl2 gradient 9/1→1/9, CH2Cl2, 
CH2Cl2/MeOH = 9/1). Final product 21 was obtained as pale yellow powder (120 mg, 37%). M.p. = 210 – 
215 °C. IR (ATR): 3084m,  2854m,  2756w,  2229s, 2011w, 1686s, 1604s, 1568w, 1438w, 1389m, 1344w, 
1303w, 1211s, 1167m, 1106m, 1059w, 1014w, 893w, 856w, 833s, 811s, 798m, 737w, 654w, 560w, 485w cm-1. 
1H NMR (500 MHz, C5D5N, δ): 10.23 (s, H-CHO), 8.36-8.33 (m, H-C(4)), 8.12 (d, J = 8.2, H-C(7)), 8.10-8.07 
(m, 2H-Ar), 7.97 (s, H-C(2)), 7.77-7.73 (m, 2H-Ar), 7.71-7.68 (m, H-C(6)). 13C NMR (125 MHz, C5D5N, δ): 
192.58, 145.72, 141.19, 138.04, 136.85, 136.31, 131.08, 130.03, 129.34, 128.19, 127.54, 125.21, 120.27, 109.35.  
3-(4-Formylphenyl)-1-benzothiophene-6-carbonitrile (22). 
Compound 22 was prepared by method C, using compound 19 (89.3 mg, 
0.375 mmol), 4-formylphenylboronic acid (70.3 mg, 0.469 mmol), 
Pd(OAc)2 (4.2 mg, 0.019 mmol), SPhos (30.8 mg, 0.0750 mmol), 2 M 
Na2CO3 (0.7 mL), DME (1 mL + 1 mL) and EtOH (1 mL) . The product 
was purified using column chromatography (dry-flash, SiO2, eluent hexane/ CH2Cl2 gradient 9/1→2/8). 
Final product 22 was obtained as white powder (75 mg, 76%). M.p. = 186 – 188 °C. IR (ATR): 3083m, 
2982w, 2837m, 2747m, 2225s, 2176w, 1998w, 1686s, 1603s, 1572m, 1489m, 1454w, 1396m, 1348m, 1307m, 
1264w, 1215s, 1171m, 1105w, 886w, 858w, 823s, 791m, 717w cm-1. 1H NMR (500 MHz, CDCl3, δ): 10.11 (s, 
H-CHO), 8.29-8.27 (m, H-C(7)), 8.06-8.02 (m, 2H-Ar), 7.99-7.96 (m, H-C(4)), 7.78 (s, H-C(2)), 7.75-7.72 (m, 
2H-Ar), 7.68-7.64 (m, H-C(5)). 13C NMR (125 MHz, CDCl3, δ): 191.56; 140.74; 140.64; 140.14; 137.06; 135.87; 
130.38; 129.46; 129.23; 127.78; 127.36; 123.41; 118.94; 108.29. HRMS: m/z 264.04675 corresponds to 
molecular formula C16H9NOSH+ (error in ppm -3.84). 
N-[4-(5-fluoro-1-benzothien-3-yl)benzyl]-N'-quinolin-4-ylpropane-1,3-diamine (23). 
Compound 23 was prepared by method A, using 
aldehyde 20 (65.3 mg, 0.255 mmol), AQ7 [1] (76.9 mg, 
0.382 mmol), glac. AcOH (22 μL, 0.38 mmol) and 
MeOH/CH2Cl2 (18 mL, 2:1, v/v). The product was 
purified using column chromatography (dry-flash, 
SiO2, eluent hexane/EtOAc gradient 1/1 → EtOAc, EtOAc/MeOH gradient 95/5 → 4/6). Final product 23 
was obtained as a pale yellow foam (66.2 mg, 59%). M.p. = 37 – 40 °C. IR (ATR): 3648w, 3254m, 3063m, 
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2927m, 2849m, 1720w, 1583s, 1542m, 1495w, 1438m, 1401w, 1371w, 1338w, 1255w, 1196w, 1132w, 884w, 
863w, 808w, 766m, 737m, 651w, 542w, 432w cm-1.  1H NMR (500MHz, CDCl3, δ): 8.51 (d, J = 5.2, H-C(2')), 
7.96 (d, J = 7.8, H-C(8’)), 7.84 (dd, J1 = 4.9, J2 = 8.8, H-C(7)),  7.71-7.67 (m, H-C(4)), 7.59-7.53 (m, 4H-Ar), 7.49-
7.46 (m, 3H-Ar), 7.26-7.22 (m, H-C(6’)), 7.18-7.12 (m, H-C(6)), 6.35 (d, J = 5.5, H-C(3')), 3.92 (s, 2H, ArCH2-), 
3.45 (t, J = 6.0, 2H, ArNHCH2-),  3.02 (t, J = 5.6, 2H, ArCH2NHCH2-), 2.64 (bs, H-N exchangeable with 
D2O), 1.99 (quin, J = 5.8, 2H, ArNHCH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 161.13 (d, J = 240.1), 150.72, 
150.50, 147.71, 139.18, 139.06 (d, J = 8.8), 137.48 (d, J = 4.5), 136.01, 134.62, 129.09, 128.91, 128.70, 125.77, 
124.34, 124.05 (d, J = 9.0), 120.47, 118.92, 113.39 (d, J = 25.3), 108.48 (d, J = 23.5), 98.00, 54.07, 49.24, 43.87, 
27.60. HRMS: m/z 221.59133 corresponds to molecular formula C27H24N3SFH22+ (error in ppm 1.38); m/z 
442.17549 corresponds to molecular formula C27H24N3SFH+ (error in ppm 1.61). HPLC purity: method A (λ 
= 330 nm): RT 11.323, area 96.48%; method B (λ = 254 nm): RT 7.986, area 95.32%. 
N1-(quinolin-4-yl)hexane-1,6-diamine AQ9. 
The general procedure D was followed using 4-chloroquinoline (300 mg, 
1.83 mmol) and 1,6-diaminohexane (1.49 g, 12.8 mmol). The final product 
was obtained as brown oil (249.8 mg, 55%). IR (ATR): 3318m, 3079m, 2928m, 
2854m, 1618w, 1582s, 1545m, 1502w, 1468w, 1439m, 1376m, 1342m, 1262w, 
1126w, 935w, 884w, 809w, 771m cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.34 (d, J = 5.5, H-C(2’)), 8.09 (d, J = 
8.5, H-C(8’)), 7.80 (d, J = 8.3, H-C(5’)), 7.63 – 7.60 (m, H-C(7’)), 7.44 – 7.41 (m, H-C(6’)), 6.48 (d, J = 5.7, H-
C(3’)), 3.35 (t, 2H, J = 3.6, H-C(1)), 2.64 – 2.61 (m, 2H, H-C(6)), 1.79 – 1.73 (m, 2H, H-C(2)), 1.53 – 1.38 (m, 
6H, 2H-C(3), 2H-C(4) and H-C(5)). 13C NMR (125 MHz, CD3OD, δ): 152.82, 151.38, 149.10, 130.54, 128.96, 
125.64, 122.32, 120.45, 99.24, 44.05, 42.60, 33.84, 29.58, 28.26, 27.94.  HRMS m/z 244.18071 corresponds to 
molecular formula C15H21N3 (error in ppm -0.49). 
N-[4-(5-fluoro-1-benzothien-3-yl)benzyl]-N'-quinolin-4-ylhexane-1,6-diamine (24). 
Compound 24 was prepared by method A, using 
aldehyde 20 (62.8 mg, 0.245 mmol), AQ9 (89.4 
mg, 0.368 mmol), glac. AcOH (21 μL, 0.37 mmol) 
and MeOH/CH2Cl2 (18 mL, 2:1, v/v). The product 
was purified using column chromatography (dry-flash, SiO2, eluent EtOAc/hexane gradient 1/9 → EtOAc, 
EtOAc/MeOH gradient 95/5 → 2/8 and flash, Biotage SP1, NH column, eluent EtOAc/hexane gradient 8/2 
→ EtOAc, EtOAc/MeOH gradient 95/5 → MeOH). Final product 24 was obtained as a pale yellow oil 
(74.2 mg, 63%). IR (ATR): 3258w, 3068w, 2930m, 2855w, 1584s, 1540m, 1495w, 1439m, 1397w, 1374w, 
1342w, 1252w, 1196w, 1117w, 884w, 864w, 809w, 768w, 738w, 652w cm-1.  1H NMR (500MHz, CDCl3, δ): 
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8.56-8.53 (m, H-C(2')), 8.00-7.96 (m, H-C(8’)), 7.81 (dd, J1 = 4.9, J2 = 8.8, H-C(7)),  7.73 (d, J = 8, H-C(5’)), 7.63-
7.58 (m, H-C(7’)), 7.58-7.53 (m, H-C(4)), 7.52-7.48 (m, H-C(10) and H-C(11)), 7.45-7.42 (m, H-C(8) and H-
C(9) and H-C(2)), 7.41-7.37 (m, H-C(6’)), 7.16-7.10 (m, H-C(6)), 6.40 (d, J = 5.4, H-C(3')), 5.09 (bs, H-N 
exchangeable with D2O), 3.85 (s, 2H, ArCH2-), 3.32-3.26 (m, 2H, ArNHCH2-), 2.69 (t, J = 7.1, 2H, 
ArCH2NHCH2-), 1.94 (bs, H-N exchangeable with D2O), 1.79-1.72 (m, 2H, ArNHCH2CH2-), 1.61-1.54 (m, 
2H, ArCH2NHCH2CH2-), 1.52-1.41 (m, 4H, ArNHCH2CH2CH2- and ArCH2NHCH2CH2CH2-). 13C NMR 
(125 MHz, CDCl3, δ): 161.03 (d, J = 240.1), 150.93, 149.67, 148.27, 140.09, 139.07 (d, J = 9.0), 137.62 (d, J = 
4.5), 135.93, 134.09, 129.80, 128.94, 128.54, 128.45, 125.51, 124.51, 123.93 (d, J = 9.0), 119.20, 118.63, 113.24 (d, 
J = 24.4), 108.47 (d, J = 23.5), 98.69, 53.74, 49.32, 43.12, 29.99, 28.82, 27.04. HRMS: m/z 484.22010 corresponds 
to molecular formula C30H30N3SFH+ (error in ppm -3.35). HPLC purity (λ = 330 nm): method A: RT 9.792, 
area 95.26%; method B: RT 8.382, area 95.22%. 
N4-(7-chloroquinolin-4-yl)-N1-[4-(5-fluoro-1-benzothien-3-yl)benzyl]pentane-1,4-diamine (25). 
Compound 25 was prepared by method A, using 
aldehyde 20 (61.5 mg, 0.240 mmol), amine N4-(7-
chloroquinolin-4-yl)pentane-1,4-diamine [1] (94.9 mg, 
0.360 mmol), glac. AcOH (21 μL, 0.36 mmol) and 
MeOH/CH2Cl2 (15 mL, 2:1, v/v). The product was 
purified using column chromatography (dry-flash, SiO2, eluent hexane/EtOAc gradient 1/1 → EtOAc, 
EtOAc/MeOH gradient 95/5 → 6/4). Final product 25 was obtained as a white powder (79.4 mg, 66%). 
M.p. = 44 – 47 °C. IR (ATR): 3247w, 3074w, 2929w, 2858w, 1607m, 1576s, 1536w, 1491w, 1441m, 1375w, 
1334w, 1252w, 1197w, 1142w, 882w, 810w, 649w cm-1.  1H NMR (500MHz, CDCl3, δ): 8.51 (d, J = 5.2, H-
C(2')), 7.94-7.93 (m, H-C(8’)), 7.83 (dd, J1 = 4.8, J2 = 8.8, H-C(7)), 7.64 (d, J = 9.2, H-C(5’)), 7.58-7.54 (m, H-
C(4)), 7.53, 7.44 (ABq, JAB = 8.2, 4H-Ar), 7.46 (s, H-C(2)), 7.28-7.24 (m, H-C(6’)), 7.15 (td, J1 = 2.8, J2 = 8.8, H-
C(6)), 6.41 (d, J = 5.5, H-C(3')), 5.35-5.30 (m, H-N exchangeable with D2O), 3.86 (s, 2H, ArCH2-), 3.77-3.68 
(m, 1H, ArNHCH(CH3)-),  2.77-2.71 (m, 2H, ArCH2NHCH2-), 1.86-1.47 (m, 5H, ArNHCH(CH3)CH2- and 
ArNHCH(CH3)CH2CH2- and H-N exchangeable with D2O), 1.33 (d, J = 6.4, 3H, ArNHCH(CH3)-). 13C 
NMR (125 MHz, CDCl3, δ): 161.08 (d, J = 240.1), 152.00, 149.35, 148.98, 139.79, 139.08 (d, J = 9.0), 137.56 (d, J 
= 3.8), 135.98, 134.73, 134.30, 128.82, 128.56, 128.54, 125.63, 125.00, 123.98 (d, J = 9.0), 121.05, 117.27, 113.31 
(d, J = 25.3), 108.49 (d, J = 23.5), 99.17, 53.75, 49.00, 48.30, 34.14, 26.47, 20.24. HRMS: m/z 252.58726 
corresponds to molecular formula C29H27ClN3SFH22+ (error in ppm 0.26); m/z 504.16695 corresponds to 
molecular formula C29H27ClN3SFH+ (error in ppm -0.30). HPLC purity: method A (λ = 330 nm): RT 9.825, 
area 97.97%; method B (λ = 254 nm): RT 8.027, area 96.12%. 
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N1-[4-(5-fluoro-1-benzothien-3-yl)benzyl]-N4-quinolin-4-ylpentane-1,4-diamine (26).  
Compound 26 was prepared by method A, using 
aldehyde 20 (94.2 mg, 0.368 mmol), amine S3 (126.4 
mg, 0.5513 mmol), glac. AcOH (30 μL, 0.5 mmol) and 
MeOH/CH2Cl2 (24 mL, 2:1, v/v). The product was 
purified using column chromatography (dry-flash, SiO2, eluent hexane/EtOAc gradient 1/1 → EtOAc, 
EtOAc/MeOH gradient 95/5 → 4/6 and flash, Biotage SP1, NH column, eluent EtOAc/hexane gradient 8/2 
→ EtOAc, EtOAc/MeOH gradient 95/5 → MeOH). Final product 26 was obtained as a colorless oil (66.1 
mg, 38%). IR (ATR): 3265w, 3068w, 2928m, 2855w, 1579s, 1536m, 1496w, 1439m, 1396w, 1341w, 1254w, 
1224w, 1196w, 1135w, 1116w, 885w, 865w, 808w, 766w, 737w cm-1. 1H NMR (500MHz, CDCl3, δ): 8.53 (d, J 
= 5.2, H-C(2')), 7.96 (d, J = 8.4, H-C(8’)), 7.82 (dd, J1 = 5.0, J2 = 8.8, H-C(7)), 7.72 (d, J = 8.2, H-C(5’)), 7.62-7.57 
(m, H-C(7’)), 7.57-7.54 (m, H-C(4)), 7.50, 7.42 (ABq, JAB = 8.0, 4H-Ar), 7.42 (s, H-C(2)), 7.37-7.32 (m, H-
C(6’)), 7.17-7.11 (m, H-C(6)), 6.42 (d, J = 5.3, H-C(3')), 5.24-5.19 (m, H-N exchangeable with D2O), 3.86 (s, 
2H, ArCH2-), 3.78-3.69 (m, 1H, ArNHCH(CH3)-),  2.78-2.70 (m, 2H, ArCH2NHCH2-), 1.85-1.50 (m, 5H, 
ArNHCH(CH3)CH2- and ArNHCH(CH3)CH2CH2- and H-N exchangeable with D2O), 1.33 (d, J = 6.4, 3H, 
ArNHCH(CH3)-). 13C NMR (125 MHz, CDCl3, δ): 161.05 (d, J = 240.1), 151.00, 148.84, 148.62, 139.91, 139.06 
(d, J = 9.0), 137.58 (d, J = 4.5), 135.94, 134.19, 129.97, 128.85, 128.53, 128.50, 125.56, 124.32, 123.95 (d, J = 9.0), 
119.31, 118.80, 113.37 (d, J = 25.3), 108.48 (d, J = 24.4), 98.86, 53.72, 49.05, 48.16, 34.18, 26.52, 20.30. HRMS: 
m/z 470.20471 corresponds to molecular formula C29H28N3SFH+ (error in ppm -2.90). HPLC purity (λ = 330 
nm): method A: RT 10.651, area 97.28%; method B: RT 8.430, area 97.16%. 
N1-[4-(5-fluoro-1-benzothien-3-yl)benzyl]-N1-methyl-N4-quinolin-4-ylpentane-1,4-diamine (27). 
Compound 27 was prepared by method E, using 
compound 26 (20.0 mg, 0.0426 mmol), 37% aqueous 
formaldehyde (6.4 μL, 0.085 mmol), ZnCl2 (11.6 mg, 
0.0852 mmol), NaBH3CN (10.7 mg, 0.170 mmol) and 
MeOH (1 mL + 1 mL). The product was purified using column chromatography (dry-flash, SiO2, eluent 
hexane/EtOAc gradient 1/1 → EtOAc, EtOAc/MeOH gradient 95/5 → 1/1 and flash, Biotage SP1, NH 
column, eluent EtOAc/hexane gradient 8/2 → EtOAc, EtOAc/MeOH gradient 95/5 → MeOH). Final 
product 27 was obtained as a colorless oil (12.3 mg, 60%). IR (ATR): 3730w, 3625w, 3276m, 3068m, 2931m, 
2851m, 2792m, 1720w, 1579s, 1536m, 1496w, 1439m, 1395w, 1342m, 1253w, 1195w, 1136w, 1115w, 1058w, 
1019w, 883w, 864w, 807w, 765w, 736w, 654w, 571w, 542w, 423w cm-1. 1H NMR (500MHz, CDCl3, δ): 8.51 
(d, J = 5.4, H-C(2')), 7.98-7.95 (m, H-C(8’)), 7.82 (dd, J1 = 4.8, J2 = 8.8, H-C(7)),  7.73-7.70 (m, H-C(5’)), 7.62-
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7.55 (m, H-C(7’) and H-C(4)), 7.50, 7.43 (ABq, JAB = 8.2, 4H-Ar), 7.46 (s, H-C(2)), 7.38-7.33 (m, H-C(6’)), 
7.17-7.11 (m, H-C(6)), 6.41 (d, J = 5.4, H-C(3')), 5.22-5.16 (m, H-N exchangeable with D2O), 3.77-3.69 (m, 
1H, ArNHCH(CH3)-), 3.56 (s, 2H, ArCH2-), 2.50-2.41 (m, 2H, ArCH2NHCH2-), 2.23 (s, 3H, CH3-N), 2.19 (bs, 
H-N exchangeable with D2O), 1.82-1.65 (m, 4H, ArNHCH(CH3)CH2- and ArNHCH(CH3)CH2CH2-), 1.33 
(d, J = 6.4, 3H, ArNHCH(CH3)-). 13C NMR (125 MHz, CDCl3, δ): 161.07 (d, J = 240.1), 150.91, 148.96, 148.52, 
139.08 (d, J = 9.0), 138.64, 137.63 (d, J = 4.5), 135.98, 134.25, 129.88, 129.49, 128.91, 128.34, 125.57, 124.34, 
123.97 (d, J = 9.0), 119.32, 118.79, 113.28 (d, J = 25.3), 108.52 (d, J = 23.5), 98.91, 62.06, 57.02, 48.11, 42.38, 
34.28, 23.91, 20.33. HRMS: m/z 484.22192 corresponds to molecular formula C30H30N3SFH+ (error in ppm 
0.41). HPLC purity (λ = 330 nm): method A: RT 9.127, area 97.38%; method B: RT 7.846, area 97.18%. 
3-[4-({[4-(quinolin-4-ylamino)butyl]amino}methyl)phenyl]-1-benzothiophene-5-carbonitrile (28). 
Compound 28 was prepared by method A, using 
aldehyde 21 (97.4 mg, 0.370 mmol), AQ8 [1] (119.5 mg, 
0.5548 mmol), glac. AcOH (32 μL, 0.55 mmol) and 
MeOH/CH2Cl2 (18 mL, 2:1, v/v). The product was 
purified using column chromatography (dry-flash, SiO2, eluent hexane/EtOAc gradient 1/1 → EtOAc, 
EtOAc/MeOH gradient 95/5 → MeOH, flash, Biotage SP1, NH column, eluent EtOac/hexane gradient 8/2 
→ EtOAc, EtOAc/MeOH gradient 95/5 → 7/3 and flash, Biotage SP1, SiO2 column, eluent 
EtOAc/MeOH+NH3 (9/1) gradient 95/5 → 8/2). Final product 28 was obtained as a white foam (35.9 mg, 
20%). M.p. = 54 – 60 °C. IR (ATR): 3280m, 3078m, 2932m, 2856m, 2225m, 1617w, 1580s, 1541m, 1495w, 
1437w, 1398w, 1374w, 1341m, 1256w, 1222w, 1129w, 1058w, 808m, 765m, 655w, 560w cm-1. 1H NMR (500 
MHz, CDCl3, δ): 8.54 (d, J = 5.2, H-C(2‘)), 8.20-8.19 (m, H-C(4)), 8.01-7.95 (m, H-C(7) and H-C(8’)), 7.75 (d, J 
= 8.2, H-C(5’)), 7.62-7.57 (m, H-C(7‘) and H-C(6)), 7.52 (s, H-C(2)), 7.51-7.46 (m, 4H-Ar), 7.37-7.32 (m, H-
C(6‘)), 6.41 (d, J = 5.2, H-C(3‘)), 5.69 (bs, H-N exchangeable with D2O), 3.92 (s, 2H, ArCH2-), 3.38-3.33 (m, 
2H, ArNHCH2-), 2.80 (t, J = 6.9, 2H, ArCH2NHCH2-), 1.94-1.81 (m, 3H, ArNHCH2CH2- and H-N 
exchangeable with D2O), 1.80-1.71 (m, 2H, ArCH2NHCH2CH2-). 13C NMR(125 MHz, CDCl3, δ): 150.91, 
149.88, 148.26, 144.75, 140.35, 137.90, 133.31, 129.75, 128.94, 128.73, 128.71, 127.71, 126.27, 125.53, 124.43, 
123.91, 119.51, 119.42, 118.76, 108.13, 98.62, 53.63, 48.73, 43.18, 27.76, 26.46. HRMS: m/z 232.10162 
corresponds to molecular formula C29H26N4SH22+ (error in ppm 1.88); m/z 463.19503 corresponds to 
molecular formula C29H26N4SH+ (error in ppm -0.14). HPLC purity: method A (λ = 330 nm): RT 8.902, area 
96.09%; method B (λ = 254 nm): RT 7.653, area 96.05%. 
3-[4-({[4-(quinolin-4-ylamino)pentyl]amino}methyl)phenyl]-1-benzothiophene-5-carbonitrile (29). 
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Compound 29 was prepared by method A, using 
aldehyde 21 (70.8 mg, 0.269 mmol), amine S3 (89.2 
mg, 0.389 mmol), glac. AcOH (23 μL, 0.39 mmol) 
and MeOH/CH2Cl2 (18 mL, 2:1, v/v). The product 
was purified using column chromatography (dry-
flash, SiO2, eluent hexane/EtOAc gradient 1/1 → EtOAc, EtOAc/MeOH gradient 95/5 → MeOH, flash, 
Biotage SP1, NH column, eluent EtOac/hexane gradient 8/2 → EtOAc, EtOAc/MeOH gradient 95/5 → 1/1 
and flash, Biotage SP1, SiO2 column, eluent EtOAc/MeOH+NH3 (9/1) gradient 95/5 → 65/35). Final 
product 29 was obtained as a white foam (28.1 mg, 21%). M.p. = 71 – 74 °C. IR (ATR): 3395w, 3267w, 
3071w, 2964w, 2929m, 2858w, 2225m, 1617w, 1577s, 1537m, 1495w, 1439m, 1395w, 1340m, 1282w, 1258w, 
1221w, 1186w, 1136w, 1058w, 1020w, 892w, 809m, 765m, 656w, 632w, 560w cm-1. 1H NMR (500 MHz, 
CDCl3, δ): 8.52 (d, J = 5.2, H-C(2’)), 8.19 (s, H-C(4)), 8.00-7.95 (m, H-C(7) and H-C(8’)), 7.74 (d, J = 8.2, H-
C(5’)), 7.63-7.56 (m, H-C(6) and H-C(7’)), 7.52 (s, H-C(2)), 7.50-7.44 (m, 4H-Ar), 7.38-7.34 (m, H-C(6’)), 6.43 
(d, J = 5.5, H-C(3’)), 5.25-5.20 (m, H-N exchangeable with D2O), 3.88 (s, 2H, ArCH2-), 3.79-3.72 (m, 1H, 
ArNHCH(CH3)-), 2.77-2.71 (m, 2H, ArNHCH(CH3)CH2CH2CH2-), 1.86-1.67 (m, 5H, ArNHCH(CH3)CH2- 
and ArNHCH(CH3)CH2CH2- and H-N exchangeable with D2O), 1.34 (d, 3H, J = 6.2, ArNHCH(CH3)-). 13C 
NMR (125 MHz, CDCl3, δ): 150.87, 148.93, 148.47, 144.74, 140.47, 137.91, 133.24, 129.86, 128.93, 128.73, 
128.66, 127.71, 126.25, 125.49, 124.39, 123.89, 119.42, 119.32, 118.77, 108.11, 98.86, 53.66, 49.04, 48.19, 34.19, 
26.52, 20.33. HRMS: m/z 239.10924 corresponds to molecular formula C30H28N4SH22+ (error in ppm 0.95); 
m/z 477.21086 corresponds to molecular formula C30H28N4SH+ (error in ppm 0.25). HPLC purity: method 
A (λ = 330 nm): RT 8.915, area 98.20%; method B (λ = 254 nm): RT 7.647, area 95.15%. 
3-[4-({[6-(quinolin-4-ylamino)hexyl]amino}methyl)phenyl]-1-benzothiophene-5-carbonitrile (30). 
Compound 30 was prepared by method A, using 
aldehyde 21 (113.8 mg, 0.4322 mmol), AQ9 (157.8 
mg, 0.6486 mmol), glac. AcOH (37 μL, 0.65 mmol) 
and MeOH/CH2Cl2 (22.5 mL, 2:1, v.v). The 
product was purified using column chromatography (dry-flash, SiO2, eluent hexane/EtOAc gradient 1/1 
→ EtOAc, EtOAc/MeOH gradient 95/5 → MeOH, flash, Biotage SP1, NH column, eluent EtOac/hexane 
gradient 8/2 → EtOAc, EtOAc/MeOH gradient 95/5 → 7/3 and flash, Biotage SP1, SiO2 column, eluent 
EtOAc/MeOH+NH3 (9/1) gradient 95/5 → 7/3). Final product 30 was obtained as a white foam (42.0 mg, 
19%). M.p. = 45 – 49 °C. IR (ATR): 3301m, 3074m, 2928s, 2853m, 2225m, 1618w, 1579s, 1540s, 1495m, 
1457w, 1436m, 1397m, 1374w, 1340m, 1254w, 1222w, 1128w, 1057w, 765m cm-1. 1H NMR (500 MHz, 
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CDCl3, δ): 8.54 (d, J = 5.2, H-C(2‘)), 8.20-8.19 (m, H-C(4)), 8.00-7.96 (m, H-C(7) and H-C(8’)), 7.73 (d, J = 8.0, 
H-C(5’)), 7.64-7.60 (m, H-C(7‘)), 7.60-7.56 (m, H-C(6)), 7.52 (s, H-C(2)), 7.50-7.46 (m, 4H-Ar), 7.44-7.39 (m, 
H-C(6‘)), 6.42 (d, J = 5.2, H-C(3‘)), 5.06 (bs, H-N exchangeable with D2O), 3.88 (s, 2H, ArCH2-), 3.36-3.30 
(m, 2H, ArNHCH2-), 2.71 (t, J = 7.1, 2H, ArCH2NHCH2-), 1.88 (bs, H-N exchangeable with D2O), 1.79 
(quin, J = 7.1, 2H, ArNHCH2CH2-), 1.60 (quin, J = 7.1, 2H, ArCH2NHCH2CH2-), 1.53-1.43 (m, 4H, 
ArNHCH2CH2CH2- and ArCH2NHCH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 151.01, 149.62, 148.37, 
144.74, 140.76, 137.98, 137.93, 133.14, 129.94, 128.92, 128.74, 128.63, 127.74, 126.24, 125.43, 124.52, 123.88, 
119.44, 119.13, 118.65, 108.10, 98.74, 53.72, 49.33, 43.16, 30.05, 28.88, 27.08. HRMS: m/z 246.11747 
corresponds to molecular formula C31H30N4SH22+ (error in ppm 2.58); m/z 491.22632 corresponds to 
molecular formula C31H30N4SH+ (error in ppm -0.15). HPLC purity: method A (λ = 330 nm): RT 9.042, area 
99.09%; method B (λ = 254 nm): RT 7.712, area 96.73%. 
3-[4-({[4-(quinolin-4-ylamino)butyl]amino}methyl)phenyl]-1-benzothiophene-6-carbonitrile (31). 
Compound 31 was prepared by method A, using 
aldehyde 22 (100.0 mg, 0.3798 mmol), AQ8 [1] 
(122.6 mg, 0.5697 mmol), glac. AcOH (33 μL, 0.57 
mmol) and MeOH/CH2Cl2 (18 mL, 2:1, v/v). The 
product was purified using column chromatography (dry-flash, SiO2, eluent hexane/EtOAc gradient 1/1 
→ EtOAc, EtOAc/MeOH gradient 9/1 → MeOH, EtOAc/MeOH(NH3 sat.)=95/5 flash, Biotage SP1, NH 
column, eluent EtOAc/hexane gradient 8/2 → EtOAc, EtOAc/MeOH gradient 95/5 → 7/3 and flash, 
Biotage SP1, SiO2 column, eluent EtOAc/MeOH+NH3 (9/1) gradient 95/5 → 8/2). Final product 31 was 
obtained as a white foam (92.2 mg, 52%). M.p. = 75 – 80 °C. IR (ATR): 3620w, 3269m, 3067m, 2935m, 
2858m, 2224s, 1616w, 1580s, 1539s, 1449m, 1396m, 1374m, 1341s, 1258w, 1194w, 1129m, 946w, 825m, 
765m, 622w cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.54 (d, J = 5.3 Hz, H-C(2’)), 8.24-8.22 (m, H-C(7)), 7.98-
7.96 (m, H-C(4)), 7.95-7.93 (m, H-C(8’)), 7.74-7.73 (m, H-C(5’)), 7.63 (s, H-C(2)), 7.61-7.57 (m, H-C(5) and 
H-C(7’)), 7.51-7.46 (m, 4H-Ar), 7.34-7.31 (m, H-C(6’)), 6.41 (d, J = 5.2 Hz, H-C(3’)), 5.69 (bs, H-N, 
exchangeable with D2O), 3.91 (s, 2H, ArCH2NH-), 3.38-3.33 (m, 2H, ArCH2NHCH2-), 2.80 (t, J = 6.9 Hz, 2H, 
ArNHCH2-), 1.94-1.88 (m, 2H, ArNHCH2CH2-), 1.82-1.72 (m, 3H, ArNHCH2CH2CH2- and H-N 
exchangeable with D2O). 13C NMR (125 MHz, CDCl3, δ): 150.95; 149.84; 148.31; 140.71; 140.53; 140.26; 
138.08; 133.49; 129.82; 128.92; 128.74; 128.66; 127.85; 127.63; 126.94; 124.41; 123.62; 119.50; 119.18; 118.77; 
107.77; 98.62; 53.66; 48.80; 43.17; 27.76; 26.45.   HRMS: m/z 463.19424 corresponds to molecular formula 
C29H26N4SH+ (error in ppm -1.85). HPLC purity (λ = 330 nm): method A: RT 8.824, area 96.60%; method B: 
RT 7.642, area 97.10%. 
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3-[4-({[6-(Quinolin-4-ylamino)hexyl]amino}methyl)phenyl]-1-benzothiophene-6-carbonitrile (32). 
Compound 32 was prepared by method A, 
using aldehyde 22 (98.0 mg, 0.372 mmol), 
AQ9 (135.9 mg, 0.5585 mmol), glac. AcOH 
(32 μL, 0.56 mmol) and MeOH/CH2Cl2 (18 
mL, 2:1, v/v). The product was purified using column chromatography (dry-flash, SiO2, eluent 
hexane/EtOAc gradient 1/1 → EtOAc, EtOAc/MeOH gradient 9/1 → MeOH, EtOAc/MeOH(NH3 sat.) = 
95/5 flash, Biotage SP1, NH column, eluent EtOAc/hexane gradient 8/2 → EtOAc, EtOAc/MeOH gradient 
95/5 → 7/3 and flash, Biotage SP1, RP column, eluent MeOH/H2O gradient 7/3 → MeOH). Final product 
32 was obtained as a white foam (60.1 mg, 33%). M.p. = 68 – 75 °C. IR (ATR): 3402m, 3266m, 3069m, 2927s, 
2853s, 2225m, 1669w, 1616w, 1580s, 1539s, 1452m, 1396m, 1374m, 1341s, 1258w, 1193w, 1127w, 1019w, 
946w, 862w, 825m, 765m, 622w cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.55 (d, J = 5.5 Hz, H-C(2’)), 8.24-8.22 
(m, H-C(7)), 7.99-7.97 (m, H-C(4)), 7.97-7.94 (m, H-C(8’)), 7.73-7.70 (m, H-C(5’)), 7.64-7.61 (m, 2H, H-C(7’) 
and H-C(2)), 7.61-7.58 (m, H-C(5)), 7.50-7.45 (m, 4H-Ar), 7.43-7.40 (m, H-C(6’)), 6.42 (d, J = 5.2 Hz, H-
C(3’)), 5.00 (bs, H-N, exchangeable with D2O), 3.87 (s, 2H, ArCH2NH-), 3.35-3.31 (m, 2H, ArCH2NHCH2-), 
2.71 (t, J = 7.1 Hz, 2H, ArNHCH2-), 1.82-1.76 (m, 2H, ArNHCH2CH2-), 1.65-1.57 (m, 3H, 
ArCH2NHCH2CH2- and H-N exchangeable with D2O), 1.53-1.46 (m, 4H, -
NHCH2CH2CH2CH2CH2CH2NH-). 13C NMR (125 MHz, CDCl3, δ): 151.03; 149.61; 148.40; 140.76; 140.66; 
140.53; 138.19; 133.34; 130.00; 128.95; 128.66; 127.77; 127.63; 126.93; 124.56; 123.65; 119.19; 119.09; 118.66; 
107.75; 98.76; 53.77; 49.45; 43.16; 30.06; 28.89; 27.09. HRMS: m/z 491.22593 corresponds to molecular 
formula C31H30N4SH + (error in ppm -0.94). HPLC purity (λ = 330 nm): method A: RT 8.949, area 98.93%; 
method B: RT 7.699, area 98.28%. 
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4-(thiophen-2-yl)benzonitrile(34). 
The general procedure F was followed using 2-bromothiophene (412 µL, 4.17 
mmol), 4-cyanophenylboronic acid (734 mg, 5.00 mmol), PdO × 1.4 H2O (6.2 mg, 
0.042 mmol), K2CO3 (691 mg, 5.00 mmol), and ethanol/water (14 mL, 3:1, v/v). The purification of final 
product was performed using hexane/toluene as eluent to obtain 34 as a white powder (635 mg, 82%).  
M.p. = 78 – 80 °C. [3] IR (film): 3094w, 2925w, 2225w, 1912w, 1666w, 1603w, 1491w, 1421m, 1352w, 1311w, 
1264w, 1211w, 1110w, 1052w, 959w, 849m, 823s, 770w, 713s cm-1. 1H NMR (500 MHz, CDCl3, δ): 7.71 – 
7.64 (m, 4H, H-C(2), H-C(3), H-C(5), H-C(6)), 7.43 – 7.40 (m, 2H, H-C(3’) and H-C(5’)), 7.13 (dd, J1 = 5.0, J2 
= 3.7, H-C(4’)). 13C NMR (125 MHz, CDCl3, δ): 142.10, 138.69, 132.76, 128.54, 127.08, 126.12, 125.12, 118.84, 
110.60. GC/MS (m/z (%)): 185.0 ([M+], 100); 140.0 (16).  
4-(5-bromothiophen-2-yl)benzonitrile (35). 
The general procedure B was followed using the solution of 34 (303 mg, 1.64 
mmol) in 1,2-dichloroethane (5 mL) and the solution of bromine (92 µL, 1.8 
mmol) in 1,2-dichloroethane (5 mL). The crude product was subjected to 
reversed-phase flash chromatography, Biotage SP1, using MeOH/H2O as eluent to afford final product 35 
as a white powder (393 mg, 91%).  M.p. = 96 °C. [4] (Ref: 98 – 99 °C) IR (film): 3092w, 2919w, 2850w, 
2229w, 1912w, 1774w, 1654w, 1602w, 1558w, 1536w, 1495w, 1426m, 1329w, 1309w, 1247w, 1209w, 1179w, 
1110w, 1067w, 977w, 942w, 834m, 804s, 737w, 661w cm-1. 1H NMR (500 MHz, CDCl3, δ): 7.67 – 7.58 (m, 
4H, 4H, H-C(2), H-C(3), H-C(5), H-C(6)), 7.16 (d, J = 3.8, H-C(3’)), 7.08 (d, J = 4.0, H-C(4’)). 13C NMR (125 
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MHz, CDCl3, δ): 143.41, 137.76, 132.88, 131.39, 125.78, 125.31, 118.64, 114.16, 111.05. GC/MS (m/z (%)): 
264.8 ([M+], 100); 140.1 (68). 
4-[5-(4-formylphenyl)thiophen-2-yl]benzonitrile (36). 
The general procedure F was followed using 35 (886 mg, 3.35 mmol), 
4-formylphenylboronic acid (603 mg, 4.02 mmol), PdO × 1.4 H2O 
(24.7 mg, 0.0419 mmol), K2CO3 (556 mg, 4.02 mmol) and 
ethanol/water (40 mL, 3:1, v/v). The purification of final product was 
performed using toluene/ethyl-acetate as eluent to obtain 36 as a yellow solid (1.07 g, 92%). M.p. = 212 – 
214 °C. IR (film): 2916w, 2849w, 2754w, 2222m, 1698s, 1598s, 1535w, 1492w, 1449w, 1396w, 1342w, 1306w, 
1277w, 1214m, 1167m, 1110w, 833s, 792s, 696w cm-1.  1H NMR (500 MHz, (CD3)2SO, δ): 10.01 (s, H-CO), 
7.98 – 7.89 (m, 8H, H-C(2), H-C(3), H-C(5), H-C(6), H-C(2’), H-C(3’), H-C(5’) and H-C(6’)), 7.84 (bs, 2H, H-
C(3”) and H-C(4”)). 13C NMR (125 MHz, (CD3)2SO, δ): 192.31, 143.19; 142.35; 138.51, 137.47, 135.30, 133.16, 
130.47, 127.90, 127.65, 125.89, 125.78, 118.74, 110.04. HRMS: m/z 290.06339 corresponds to molecular 
formula C18H11NOSH+ (error in ppm -0.08). 
4-(5-{4-[({2-[(7-chloroquinolin-4-yl)amino]ethyl}amino)methyl]phenyl}-2-thienyl)benzonitrile (37). 
The general procedure A was followed using 36 (59.3 
mg, 0.205 mmol), AQ2 (66.5mg, 0.299 mmol), MeOH/ 
CH2Cl2 (5.3 mL, 2:1, v/v), glac. AcOH (18 µL, 0.30 
mmol) and NaBH4 (45.4 mg, 1.20 mmol). After 
working up the reaction in a manner provided in a general procedure, the crude product was subjected to 
silica-gel column chromatography using EtOAc/MeOH as eluent and NH flash chromatography, Biotage 
SP1, using hexane/EtOAc and EtOAc/MeOH as eluents. The final product 37 was obtained as a yellow 
solid (33 mg, 32%). M.p. = 147 – 149 °C. IR (film): 3245w, 3067w, 2954w, 2841w, 2224w, 1603w, 1579s, 
1541w, 1493w, 1452w, 1432w, 1367w, 1333w, 1279w, 1250w, 1206w, 1139w, 878w, 837w, 793m, 767w, 
737w, 705w, 684w, 659w, 650w, 620w, 604w, 601w cm-1. 1H NMR (500 MHz, CDCl3 + CD3OD, δ): 8.41 (d, J 
= 5.5, H-C(2'')), 7.90 (d, J = 2.1, H-C(8'')), 7.83 (d, J = 8.9, H- C(5'')), 7.71, 7.67 (ABq, 4H, JAB = 8.4, H-C(2), H-
C(3), H-C(5) and H-C(6)), 7.59, 7.36 (ABq, 4H, JAB = 8.1, H-C(2'), H-C(3'), H-C(5') and H-C(6')), 7.42, 7.32 
(Abq, JAB = 3.7, 2H, H-ArS), 7.39 (dd, J1 = 2.1, J2 = 8.9, H-C(6'')), 6.38 (d, J = 5.5, H-C(3'')), 3.87 (s, 2H, ArCH2-
), 3.43 – 3.39 (m, 2H, ArNHCH2-, ovlp with solvent signal), 3.06 – 3.04 (m, 2H, ArNHCH2CH2-). 13C NMR 
(125 MHz, CDCl3 + CD3OD, δ): 151.32, 150.29, 148.38, 145.42, 140.87, 139.17, 138.45, 135.15, 132.79, 132.67, 
128.76, 127.58, 126.08, 125.85, 125.60, 125.33, 124.32, 121.66, 118.74, 117.21, 98.74, 52.88, 46.67, 42.01. HRMS: 
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m/z 495.13994 corresponds to molecular formula C29H23ClN4SH+ (error in ppm -1.06). HPLC purity (λ = 
330 nm): method E: RT 6.741, area 96.66%, method F: RT 7.940, area 96.79%. 
4-(5-{4-[({3-[(7-chloroquinolin-4-yl)amino]propyl}amino)methyl]phenyl}-2-thienyl)benzonitrile (38). 
The general procedure A was followed using 36 
(137.2 mg, 0.4742 mmol), AQ3 (168 mg, 0.711 
mmol), MeOH/ CH2Cl2 (12 mL, 2:1, v/v), glac. 
AcOH (43 µL, 0.71 mmol) and NaBH4 (107.6 
mg, 2.844 mmol). After working up the reaction 
in a manner provided in a general procedure, the crude product was subjected to silica-gel column 
chromatography using EtOAc/MeOH as eluent and NH flash chromatography, Biotage SP1, using 
hexane/EtOAc and EtOAc/MeOH as eluents. The final product 38 was obtained as a yellow solid (141.8 
mg, 59%). M.p. = 138 – 140 °C. IR (film): 3248 m, 3066w, 2946w, 2907w, 2846m, 2560w, 2357w, 2223m, 
2184w, 2166w, 2097w, 1987w, 1962w, 1918w, 1602m, 1579s, 1537m, 1494m, 1450m, 1426m, 1364w, 1332m, 
1281m, 1240w, 1183w, 1136m, 1106w, 1070w, 953w, 897w, 851m, 798m, 763w, 615w, 541w cm-1. 1H NMR 
(500 MHz, CDCl3, δ): 8.50 (d, J = 5.3, H-C(2'')), 7.91 (d, J = 2.2, H-C(8'')), 7.69, 7.67 (ABq, 4H, J = 8.7, H-C(2), 
H-C(3), H-C(5) and H-C(6)), 7.61, 7.37 (ABq, 4 H, J = 8.3, H-C(2’), H-C(3’), H-C(5’), H-C(6’)), 7.50 (d, J = 8.9, 
H-C(5'')), 7.48 – 7.44 (m, H-N, exchangeable with D2O), 7.42, 7.34 (ABq, 2H, J = 3.9, H-ArS), 7.12 (dd, J1 = 
2.2, J2 = 8.9, H-C(6'')), 6.32 (d, J = 5.4, H-C(3'')), 3.87 (s, 2H, ArCH2-), 3.42 – 3.39 (m, 2H, ArNHCH2-), 3.00 – 
2.98 (m, 2H, -CH2NHCH2CH2-), 1.98 – 1.94 (m, 2H, -CH2CH2CH2-), 1.68 (bs, H-N, exchangeable with D2O). 
13C NMR (125 MHz, CDCl3, δ): 152.18, 150.36, 149.19, 145.53, 141.09, 139.64, 138.49, 134.55, 132.91, 132.76, 
129.06, 128.58, 126.17, 126.03, 125.71, 124.82, 124.46, 122.03, 118.85, 117.51, 110.48, 98.37, 53.94, 49.26, 43.92, 
27.49. HRMS: m/z 509.15630 corresponds to molecular formula C30H25ClN4SH+ (error in ppm 0.35). HPLC 
purity (λ = 330 nm): method C: RT 8.427, area 97.74%, method D: RT 7.073, area 98.21%. 
4-(5-{4-[({4-[(7-chloroquinolin-4-yl)amino]butyl}amino)methyl]phenyl}-2-thienyl)benzonitrile (39). 
The general procedure A was 
followed using 36 (60 mg, 0.2 mmol), 
AQ4 (77.7 mg, 0.311 mmol), 
MeOH/CH2Cl2 (5.3 mL, 2:1, v/v), glac. 
AcOH (19 µL, 0.31 mmol) and NaBH4 (47 mg, 1.2 mmol). After working up the reaction in a manner 
provided in a general procedure, the crude product was subjected to silica-gel column chromatography 
using EtOAc/MeOH as eluent and NH flash chromatography, Biotage SP1, using hexane/EtOAc and 
EtOAc/MeOH as eluents. The final product 39 was obtained as a yellow solid (41.2 mg, 38%). M.p. = 163 – 
4 S NH
NHNC N
Cl
4'
2"
S NHNC
NH
N
Cl
4
2"
4'
S23 
 
164 °C. IR (film): 3278w, 3068w, 2935m, 222w, 1583s, 1544w, 1494w, 1451m, 1366w, 1338w, 1281w, 1209w, 
1175w, 1139w, 1034w, 882w, 825m, 797m, 771w cm-1. 1H NMR (500 MHz, CDCl3 + CD3OD, δ): 8.42 (d, J = 
5.5, H-C(2'')), 7.89 (d, J = 2.1, H- C(8'')), 7.77 (d, J = 8.9, H-C(5'')), 7.71, 7.66 (ABq, 4H,   JAB = 8.6, H-C(2), H-
C(3), H-C(5) and H-C(6)), 7.60, 7.35 (ABq, 4H, JAB = 8.1, H-C(2'), H-C(3'), H-C(5') and H-C(6')), 7.41, 7.32 
(ABq, 2H, JAB = 3.9, H-ArS), 7.30 – 7.27 (m, H-C(6'')), 6.37 (d, J = 5.6, H-C(3'')), 3.83 (s, 2H, ArCH2-), 3.32 (t, 
2H, J = 6.6, ArNHCH2-), 2.74 (t, 2H, J = 6.9, ArCH2NHCH2-), 1.86 – 1.81 (m, 2H, ArNHCH2CH2-), 1.74 – 1.69 
(m, 2H, ArNHCH2CH2CH2- ). 13C NMR (125 MHz, CDCl3 + CD3OD, δ): 151.41, 148.48, 145.54, 140.87, 
139.27, 138.47, 135.02, 132.73, 132.69, 128.79, 127.72, 126.08, 125.85, 125.62, 125.12, 124.31, 121.59, 118.78, 
117.13, 110.23, 98.61, 53.31, 48.35, 42.84, 27.27, 26.03. HRMS: m/z 523.17161 corresponds to molecular 
formula C31H27ClN4SH+ (error in ppm -0.32). HPLC purity (λ = 330 nm): method C: RT 8.278, area 95.92%, 
method D: RT 7.072, area 96.32%. 
4-(5-{4-[({5-[(7-chloroquinolin-4-yl)amino]pentyl}amino)methyl]phenyl}-2-thienyl)benzonitrile (40). 
The general procedure A was 
followed using 36 (70.0 mg, 0.242 
mmol), AQ5 [2] (95.4 mg, 0.362 
mmol), MeOH/CH2Cl2 (6 mL, 2:1, 
v/v), glac. AcOH (22 µL, 0.36 mmol) 
and NaBH4 (54.8 mg, 1.45 mmol).  After working up the reaction in a manner provided in a general 
procedure A, the crude product was subjected to silica-gel column chromatography using EtOAc/MeOH 
as eluent and NH flash chromatography, Biotage SP1, using hexane/EtOAc and EtOAc/MeOH as eluent. 
The final product 40 was obtained as a yellow solid (31.4 mg, 40%). M.p. = 150 – 152 °C. IR (film): 3405m, 
3022w, 2988w, 2932m, 2858m, 2823w, 2219m, 2182w, 1604m, 1582s, 1531m, 1498w, 1478m, 1450m, 1371w, 
1335w, 1278w, 1180w, 1134w, 1107w, 1076w, 902w, 879w, 850w, 831w, 801m, 739w cm-1. 1H NMR (500 
MHz, CDCl3 + CD3OD, δ): 8.25 (d, J = 5.5, H-C(2'')), 7.73 (d, J = 2.1, H-C(8'')), 7.63 (d, J = 9.0, H-C(5'')), 7.54, 
7.50 (ABq, 4H, JAB = 8.6, H-C(2), H-C(3), H-C(5) and H-C(6)), 7.45 – 7.43 (m, 2H, H- C(2') and H-C(6')), 7.24 
(d, J = 3.9, H-ArS), 7.19 – 7.15 (m, 4H, H-C(3'), H-C(5'), H-ArS and H-C(6'')), 6.22 (d, J = 5.6, H-C(3'')), 3.65 
(s, 2H, ArCH2-), 3.16 (t, 2H, J = 7.0, ArNHCH2-), 2.79 (s, H-N, exchangeable with D2O), 2.52 (t, 2H, J = 7.1, 
ArCH2NHCH2-), 1.63 – 1.57 (m, 2H, ArNHCH2CH2-), 1.49 – 1.43 (m, 2H, -CH2NHCH2CH2-), 1.38 – 1.31 (m, 
2H, ArNHCH2CH2CH2-). 13C NMR (125 MHz, CDCl3 + CD3OD, δ): 151.29, 150.29, 148.39, 145.55, 140.76, 
139.23, 138.45, 135.02, 132.64, 128.82, 127.58, 126.06, 125.76, 125.56, 125.13, 124.25, 121.49, 118.75, 117.03, 
110.12, 98.60, 53.21, 48.54, 42.73, 29.08, 28.09, 24.53. HRMS: m/z 537.18574 corresponds to molecular 
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formula C32H29ClN4SH+ (error in ppm -3.13). HPLC purity (λ = 330 nm): method C: RT 8.209, area 98.02%, 
method D: RT 6.985, area 97.40%. 
4-(5-{4-[({6-[(7-chloroquinolin-4-yl)amino]hexyl}amino)methyl]phenyl}-2-thienyl)benzonitrile (41). 
The general procedure A was 
followed using 36 (279 mg, 
0.964 mmol), AQ6 (401.7 mg, 
1.466 mmol), MeOH/CH2Cl2 
(23.5 mL, 2:1, v/v), glac. AcOH (87 µL, 1.4 mmol) and NaBH4 (218.8 mg, 5.784 mmol). After working up 
the reaction in a manner provided in a general procedure, the crude product was subjected to silica-gel 
column chromatography using EtOAc/MeOH as eluent and NH flash chromatography, Biotage SP1, 
using hexane/EtOAc and EtOAc/MeOH as eluents. The final product 41 was obtained as a yellow solid 
(205.7 mg, 39%). M.p. = 130 – 131 °C. IR (film): 3411w, 3059w, 2927w, 2854w, 2221w, 1578s, 1451m, 1365w, 
1323w, 1132w, 833w, 797w cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.51 (d, J = 8.3, H-C(2''), 7.95 (d, J = 
2.1, H-C(5''), 7.70 – 7.58 (m, 7H, H-C(2), H-C(3), H-C(5), H-C(6), H-C(8''), H-C(2’), H-C(6’)), 7.39 – 7.33 (m, 
4H, H-ArS, H-C(3’), H-C(5’), H-C(6'')), 7.30 (d, J = 3.7, H-ArS), 6.40 (d, J = 5.5, H-C(3'')), 3.82 (s, 2H, ArCH2-
), 3.30 (t, J = 7.2, 2H, ArNHCH2-), 2.65 (t, J = 7.1, 2H, ArCH2NHCH2-), 1.79 – 1.73 (m, 2H, ArNHCH2CH2-), 
1.59 – 1.43 (m, 6H, ArNHCH2CH2CH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 152.05, 149.68, 149.13, 
145.94, 140.78, 140.64, 138.55, 134.86, 132.76, 132.44, 128.89, 128.79, 126.10, 125.81, 125.68, 125.29, 124.22, 
120.76, 118.88, 117.10, 110.42, 99.10, 53.68, 49.24, 43.21, 30.00, 28.85, 27.05. HRMS: m/z 551.20336 
corresponds to molecular formula C33H31ClN4SH+ (error in ppm 0.53). HPLC purity (λ = 330 nm): method 
A: RT 8.681, area 95.22%, method B: RT 7.415, area 95.74%. 
N-(7-chloroquinolin-4-yl)octane-1,8-diamine AQ88. 
The general procedure D was followed using 4,7-dichloroquinoline 
(500 mg, 2 mmol) and 1,8-diaminooctane (1.8 g, 13 mmol). The final 
product AQ88 was obtained as a pale yellow solid (535.6 mg, 69%). 
M.p. = 97 – 98 °C. IR (ATR): 3325m, 3262m, 2928m, 2851m, 1612m, 
1577m, 1537m, 1480w, 1449w, 1431w, 1369m, 1330w, 1281w, 1251w, 1198w, 1134w, 1080w, 1027w, 960w, 
922w, 903w, 876w, 852w, 809w, 771w, 729w, 649 cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.51 (d, J = 5.4, 
H-C(2’)), 7.95 (d, J = 2.1, H-C(8’)), 7.66 (d, J = 8.9, H-C(5’)), 7.34 (dd, J1 = 8.9, J2 = 2.1, H-C(6’)), 6.40 (d, J = 5.4, 
H-C(3’)), 3.29 (t, 2H, J = 7.2, H-C(1)), 2.66 (t, 2H, J = 7.0, H-C(8)), 1.78 – 1.72 (m, 2H, H-C(2)), 1.48 – 1.32 (m, 
10H, H-C(3), H-C(4), H-C(5), H-C(6) and H-C(7)). 13C NMR (125 MHz, CDCl3, δ): 152.02, 149.68, 149.12, 
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134.74, 128.79, 125.16, 120.83, 117.09, 99.02, 43.22, 42.16, 33.70, 29.34, 29.28, 28.84, 27.05, 26.76. HRMS: m/z 
306.17168 corresponds to molecular formula C17H24N3ClH+ (error in ppm -4.82). 
4-(5-{4-[({8-[(7-chloroquinolin-4-yl)amino]octyl}amino)methyl]phenyl}-2-thienyl)benzonitrile (42). 
The general procedure A 
was followed using 36 
(242 mg, 0.835 mmol), 
AQ88 (383.4 mg, 1.253 
mmol), MeOH/CH2Cl2 
(23.5 mL, 2:1, v/v), glac. AcOH (75 µL, 1.2 mmol) and NaBH4 (189.5 mg, 5.009 mmol).  After working up 
the reaction in a manner provided in a general procedure A, the crude product was subjected to silica-gel 
column chromatography using EtOAc/MeOH as eluent and NH flash chromatography, Biotage SP1, 
using hexane/EtOAc and EtOAc/MeOH as eluents. The final product 42 was obtained as a pale yellow 
solid (173.8 mg, 36%). M.p. = 123 – 125 °C. IR (film): 3641w, 3612w, 3298m, 3072m, 2930s, 2855m, 2222m, 
2173w, 1602m, 1581s, 1543m, 1495m, 1471m, 1450m, 1373m, 1332m, 1280w, 1207w, 1177w, 1137w, 1076w, 
1022w, 907w, 877w, 840m, 798m, 770w, 733w, 648w, 538w cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.51 
(d, J = 5.4, H-C(2'')), 7.95 (d, J = 2.0, H-C(8'')), 7.69 – 7.57 (m, 7H, H-C(2), H-C(3), H-C(5), H-C(6), H-C(2’), 
H-C(6’), H-C(5'')), 7.38 – 7.29 (m, 5H, H-(3’), H-C(5’), 2H-ArS, H-C(6'')), 6.39 (d, J = 5.3, H-C(3'')), 3.80 (s, 
ArCH2NH-), 3.28 (t, 2H, J = 7.1, ArNHCH2-), 2.63 (t, 2H, J = 7.2,  ArCH2NHCH2-), 1.77 – 1.71 (m, 2H, 
ArNHCH2CH2-), 1.54 – 1.42 (m, 4H, ArNHCH2CH2CH2CH2CH2CH2CH2-), 1.42 – 1.29 (m, 6H, 
CH2NHCH2CH2CH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 152.01, 149.67, 149.08, 145.93, 140.69, 138.50, 
134.78, 132.70, 132.33, 128.80, 128.74, 126.05, 125.74, 125.61, 125.20, 124.14, 120.76, 118.84, 117.07, 110.32, 
99.03, 53.64, 49.38, 43.23, 30.02, 29.38, 29.24, 28.84, 27.21, 27.04.  HRMS: m/z 579.23307 corresponds to 
molecular formula C35H35N4SClH+ (error in ppm -2.25). HPLC purity (λ = 330 nm): method D: RT 11.456, 
area 96.24%, method G: RT 6.658, area 99.44%. 
4-{5-[4-({[4-(quinolin-4-ylamino)butyl]amino}methyl)phenyl]-2-thienyl}benzonitrile (43). 
 
The general procedure A was followed 
using 36 (70.0 mg, 0.241 mmol), AQ8 [1] 
(77.5 mg, 0.360 mmol), MeOH/CH2Cl2 (6 
mL, 2:1, v/v), glac. AcOH (22 µL, 0.36 
mmol) and NaBH4 (54.5 mg, 1.44 mmol).  After working up the reaction in a manner provided in a 
general procedure, the crude product was subjected to silica-gel column chromatography using 
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EtOAc/MeOH as eluent and NH flash chromatography, Biotage SP1, using hexane/EtOAc and 
EtOAc/MeOH as eluent. The final product 43 was obtained as a yellow solid (53 mg, 45%). M.p. = 117 – 
118 °C. IR (film): 3401m, 3273m, 3067m, 2930m, 2856m, 2225m, 1584s, 1543m, 1497w, 1454m, 1376w, 
1344m, 1279w, 1129w, 839w, 804m, 767w, 737w cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.53 (d, J = 5.3, 
H-C(2'')), 7.98 – 7.96 (m, H-C(8'')), 7.73 – 7.58 (m, 8H, H-C(5''), H-C(2), H-C(3), H-C(5), H-C(6), H-C(7''), H-
C(2’) and H-C(6’)), 7.40 – 7.31 (m, 5H, 2H-ArS, H-C(3’), H-C(5’), H-C(6'')), 6.40 (d, J = 5.3, H-C(3'')), 3.84 (s, 
2H, Ar-CH2), 3.34 (t, J = 6.7, 2H, ArNHCH2-), 2.75 (t, J = 6.8, 2H, -CH2NHCH2CH2-), 1.91 – 1.85 (m, 2H, 
ArNHCH2CH2-), 1.75 – 1.70 (m, 2H, -CH2NHCH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 150.94, 149.85, 
148.27, 145.80, 140.80, 140.26, 138.49, 132.71, 129.75, 128.93, 128.73, 126.08, 125.83, 125.64, 124.42, 124.24, 
119.49, 118.84, 118.76, 110.37, 98.60, 53.55, 48.62, 43.14, 27.70, 26.40. HRMS: m/z 489.21074 corresponds to 
molecular formula C31H28N4SH+ (error in ppm -3.81). HPLC purity (λ = 330 nm): method C: RT 8.238, area 
96.23%, method D: RT 6.871, area 96.87%. 
4-{5-[4-({[6-(quinolin-4-ylamino)hexyl]amino}methyl)phenyl]-2-thienyl}benzonitrile (44). 
 
The general procedure A was 
followed using 36 (70.0 mg, 0.241 
mmol), AQ9 (88 mg, 0.36 mmol), 
MeOH/CH2Cl2 (6 mL, 2:1, v/v), 
glac. AcOH (22 µL, 0.36 mmol) 
and NaBH4 (54.9 mg, 1.45 mmol). After working up the reaction in a manner provided in a general 
procedure A, the crude product was subjected to silica-gel column chromatography using EtOAc/MeOH 
as eluent and NH flash chromatography, Biotage SP1, using hexane/EtOAc and EtOAc/MeOH eluent. 
The final product 44 was obtained as a yellow solid (33 mg, 26%). M.p. = 117 – 119 °C. IR (film): 3298w, 
3068w, 2926m, 2853m, 2224m, 1729w, 1581s, 1541m, 1496m, 1452m, 1375w, 1342m, 1279w, 1224w, 1177w, 
1126w, 1017w, 972w, 837w, 801m, 765m, 733w, 671w cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.55 (d, J = 5.3, 
H-C(2'')), 7.98 (d, J = 7.8, H-C(8'')), 7.72 – 7.58 (m, 8H, H-C(5''), H-C(2), H-C(3), H-C(5), H-C(6), H-C(7''), H-
C(2’) and H-C(6’)), 7.73 – 7.35 (m, 4H, H-C(6''), H-ArS, H-C(2’) and H-C(6’)), 7.30 (d, J = 3.9, H-ArS), 6.42 
(d, J = 5.5, H-C(3'')), 4.97 (bs, H-N), 3.82 (s, 2H, Ar-CH2), 3.33 – 3.29 (m, 2H, ArNHCH2-), 2.66 (t, J = 7.1, 2H, 
-CH2NHCH2CH2-), 1.80 – 1.74 (m, 2H, ArNHCH2CH2-), 1.60 – 1.54 (m, 2H, -CH2NHCH2CH2-), 1.52 – 1.42 
(m, 4H, ArNHCH2CH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 151.06, 149.59, 148.43, 145.94, 140.72, 
138.52, 132.72, 132.36, 130.02, 128.92, 128.73, 126.06, 125.77, 125.63, 124.54, 124.17, 119.09, 118.85, 118.66, 
110.36, 98.77, 53.67, 49.27, 43.15, 30.03, 28.88, 27.05. HRMS: m/z 517.24197 corresponds to molecular 
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formula C33H32N4SH+ (error in ppm -0.14). HPLC purity (λ = 330 nm): method A: RT 7.995, area 95.20%, 
method B: RT 9.836, area 95.69%. 
4-{5-[4-({[8-(quinolin-4-ylamino)octyl]amino}methyl)phenyl]-2-thienyl}benzonitrile (45). 
The general procedure A was 
followed using 36 (96.0 mg, 
0.332 mmol), AQ10 (135 mg, 
0.497 mmol), MeOH/CH2Cl2 
(7.5 mL, 2:1, v/v), glac. AcOH 
(31 µL, 0.50 mmol) and NaBH4 (75.3 mg, 1.99 mmol). After working up the reaction in a manner provided 
in a general procedure A, the crude product was subjected to silica-gel column chromatography using 
EtOAc/MeOH as eluent and NH flash chromatography, Biotage SP1, using hexane/EtOAc and 
EtOAc/MeOH as eluents. The final product 45 was obtained as a yellow solid (62.7 mg, 35 %). M.p. = 110 
– 112 °C. IR (film): 3255m, 3072m, 2928s, 2854m, 2226m, 1582s, 1541m, 1496w, 1454m, 1396w, 1375w, 
1343m, 1280w, 1179w, 1128w, 838w, 803m, 766w, 737w cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.54 (d, 
J =5.4, H-C(2'')), 7.98 (d, J = 8.3, H-C(8'')), 7.72 – 7.58 (m, 8H, H-C(5''), H-C(7''), H-C(2), H-C(3), H-C(5), H-
C(6), H-C(2’) and H-C(6’)), 7.43 – 7.35 (m, 4H, H-C(6''), H-ArS and H-C(3’) and H-C(5’)), 7.30 (d, J = 3.8, H-
ArS), 6.4 (d, J = 5.3, H-C(3'')), 3.80 (s, 2H, ArCH2-), 3.30 (t, J = 7.1, 2H, ArNHCH2-), 2.63 (t, J = 7.2, 2H, -
CH2NHCH2CH2-), 1.78 – 1.72 (m, 2H, ArNHCH2CH2-), 1.54 – 1.35 (m, 10H, -
CH2NHCH2CH2CH2CH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 151.01, 149.64, 148.35, 145.96, 140.73, 
140.70, 138.52, 132.72, 132.34, 129.94, 128.94, 128.75, 126.06, 125.76, 125.63, 124.54, 124.16, 119.09, 118.84, 
118.64, 110.35, 98.74, 53.66, 49.42, 43.22, 30.05, 29.41, 29.27, 28.91, 27.22, 27.07. HRMS: m/z 545.27237 
corresponds to molecular formula C35H36N4SH+ (error in ppm -1.78).  
4-{5-[4-({methyl[8-(quinolin-4-ylamino)octyl]amino}methyl)phenyl]-2-thienyl}benzonitrile (46). 
The general procedure E was 
followed using the solution of 
45 (47.9 mg, 0.0879 mmol) in 
MeOH (2 mL), 37 % aqueous 
formaldehyde (13.2 µL, 0.176 
mmol) and a mixture of ZnCl2 (24.0 mg, 0.176 mmol), NaBH3CN (22.1 mg, 0.352 mmol) and MeOH (2 
mL). After working up the reaction in a manner provided in a general procedure E, the crude product 
was subjected to NH flash chromatography, Biotage SP1, using hexane/EtOAc and EtOAc/MeOH as 
eluents. The final product 46 was obtained as a yellow solid (23.4 mg, 45 %). Mp = 99 – 100 °C. IR (film): 
S
N N N
H
N
H
2
3
5
2'
3'
5'
6'
2"
3"
5"
6"
7"
8"
6
S
N N N
H
N
2
3
5
2'
3'
5'
6'
2"
3"
5"
6"
7"
8"
6
S28 
 
3285m, 3056m, 2926s, 2853s, 2225m, 1602s, 1582s, 1541s, 1497m, 1456s, 1372m, 1343m, 1273m, 1176m, 
1124m, 1068m, 1016w, 838m, 802m, 765m, 736m cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.53 (d, J = 5.2, 
H-C(2'')), 7.98 (d, J = 8.4, H-C(8'')), 7.71 – 7.57 (m, 8H, H-C(5''), H-C(7''), H-C(2), H-C(3), H-C(5), H-C(6), H-
C(2’) and H-C(6’)), 7.43 – 7.40 (m, 4H, H-C(6''), H-ArS, H-C(3’) and H-C(5’)), 7.30 (d, J = 3.9, H-ArS), 6.41 
(d, J = 5.4, H-C(3'')), 3.50 (s, 2H, Ar-CH2), 3.29 (t, J = 7.2, 2H, ArNHCH2-), 2.39 – 2.36 (m, 2H, -
CH2N(CH3)CH2-), 2.21 (s, 3H, CH3N), 1.78 – 1.72 (m, 2H, ArNHCH2CH2-), 1.54 – 1.33 (m, 10H, ArCH2 
N(CH3)CH2CH2CH2CH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 151.00, 149.69, 148.35, 146.08, 140.68, 
139.67, 138.56, 132.75, 132.35, 129.96, 129.68, 129.00, 126.09, 125.65, 125.60, 124.58, 124.14, 119.11, 118.89, 
118.66, 110.37, 98.78, 62.02, 57.45, 43.29, 42.36, 29.44, 29.34, 28.97, 27.38, 27.30, 27.14. HRMS: m/z 559.28899 
corresponds to molecular formula C36H38N4SH+ (error in ppm -2.13). HPLC purity (λ = 330 nm): method I: 
RT 5.420, area 95.23 %, method H: RT 4.826, area 96.54 %. 
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4-(2-thienyl)benzaldehyde (47). 
The general procedure G was followed using Pd(OAc)2 (68.8 mg, 0.306 mmol) 
and PPh3 (321.6 mg, 1.226 mmol) in toluene (35 mL), 2-bromothiophene (594 µL, 
6.13 mmol), 4-formylphenylboronic acid (1.01 g, 6.74 mmol) and 2M aq. Na2CO3  
(6 mL) in MeOH (6 mL). After colling to room temperature, the reaction mixture 
was extracted with CH2Cl2, organic layers were washed with brine and dried over anh. Na2SO4. After 
filtration, the solvent was removed under reduced pressure. The crude product was subjected to silica-gel 
flash chromatography, Biotage SP1, using hexane / EtOAc as eluent. The final product 47 was obtained as 
a pale yellow solid (1.00 g, 87%). M.p. = 60 – 61 °C. [5] IR (ATR): 3107w, 2926w, 2851w, 2738w, 2005w, 
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1703s, 1604m, 1565w, 1426w, 1216w, 1174w, 822m, 708w cm-1. 1H NMR (500 MHz, CDCl3, δ): 10.00 (s, H-
CO), 7.90 – 7.76 (m, 4H, H-C(2), H-C(3), H-C(5) and H-C(6)), 7.47 – 7.40 (m, 2H, H-C(3’) and H-C(5’)), 7.15 
– 7.13 (m, H-C(4’)). 13C NMR (125 MHz, CDCl3, δ): 191.47, 142.74, 140.12, 135.10, 130.47, 128.47, 126.92, 
126.05, 125.03. GC/MS (m/z (%)): 188.0 ([M+], 100); 115.1 (40). 
4-(5-bromo-2-thienyl)benzaldehyde (48). 
N-bromosuccinimide (228.9 mg, 1.286 mmol) was added to the stirring solution 
of 47 (226.4 mg, 1.203 mmol) in dry THF (11 mL) in the dark, at room 
temperature. Reaction progress was monitored by TLC (RP, MeOH). After 4h of 
stirring, an aq. Na2S2O3 solution was added, and the desired product was 
extracted with CH2Cl2. Combined organic layers were washed with brine, and dried over anh. Na2SO4. 
After filtration, the solvent was removed under reduced pressure. The crude product was subjected to 
reversed-phase flash chromatography, Biotage SP1, using MeOH/H2O as eluent. The final product 48 was 
obtained as an orange solid (256.1 mg, 80%). M.p. = 117 - 118 °C. IR (ATR): 3477s, 2922m, 2851m, 2759w, 
1692s, 1666m, 1604m, 1566w, 1425m, 1397w, 1220w, 1204w, 1175m, 1110w, 832w, 796m, 686w, 652w cm-1. 
1H NMR (500 MHz, CDCl3, δ): 10.00 (s, H-CO), 7.88, 7.66 (ABq, JAB = 8.3, 4H, H-C(2), H-C(3), H-C(5) and 
H-C(6)), 7.20, 7.09 (ABq, JAB = 3.9, 2H, H-C(3’) and H-C(4’)). 13C NMR (125 MHz, CDCl3, δ): 191.29, 144.08, 
139.14, 135.36, 131.32, 130.53, 125.70, 125.18, 113.92. GC/MS (m/z (%)): 267.9 ([M+], 100); 158.0 (66).  
4-[5-(4-bromophenyl)-2-thienyl]benzaldehyde (49). 
The general procedure G was followed using Pd(OAc)2 (14.6 mg, 
0.0650 mmol) and PPh3 (68.7 mg, 0.262 mmol) in toluene (15 mL), 48 
(350 mg, 1.3 mmol), 4-bromophenylboronic acid (289.2 mg, 1.440 
mmol) and 2M aq. Na2CO3  (1.3 mL) in MeOH (6 mL) and toluene (15 mL). After colling to room 
temperature, the reaction mixture was diluted with CH2Cl2, filtered through a small pad of celite and 
dried over anh. Na2SO4. After filtration, the solvent was removed under reduced pressure. The crude 
product was subjected to silica-gel flash chromatography, Biotage SP1, using hexane / EtOAc as eluent. 
The final product 49 was obtained as a pale yellow solid (249.6 mg, 56%). IR (ATR): 3435s, 2922w, 2852w, 
2728w, 1698s, 1662w, 1560s, 1564w, 1541w, 1508w, 1438w, 1450w, 1418w, 1394w, 1338w, 1307w, 1277w, 
1213m, 1169m, 1112w, 1068w, 1007w, 939w, 831m, 803s, 695w, 671w, 633w cm-1. 1H NMR (500 MHz, 
CDCl3, δ): 10.01 (s, H-CO), 7.90, 7.76 (ABq, 4H, JAB = 8.4, H-C(2), H-C(3), H-C(5) and H-C(6)),   7.53, 7.50 
(ABq, 4H, JAB = 8.8, H-C(2''), H-C(3''), H-C(5'') and H-C(6'')), 7.02, 6.83 (ABq, 2H, JAB = 4.0, H-C(3’) and H-
C(4’)). 13C NMR (125 MHz, CDCl3, δ): 191.32, 144.42, 142.15, 139.72, 135.16, 132.76, 132.11, 130.48, 127.16, 
126.08, 125.70, 124.73, 121.90. GC/MS (m/z (%)): 343.9 ([M+], 100); 234.0 (54). 
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4-(5-{4-[(trimethylsilyl)ethynyl]phenyl}-2-thienyl)benzaldehyde (50). 
To a solution of 49 (71 mg, 0.21 mmol) in DMF (1 mL), 
PdCl2(PPh3)2 (8.7 mg, 0.012 mmol), PPh3 (10.8 mg, 0.0412 
mmol), ethinyltrimethylsilane (32 µL, 0.027 mmol), CuI (2.3 
mg, 0.012 mmol), and Et2NH (323 µL, 3.12 mmol) were 
added under an argon atmosphere. The reaction mixture was subjected to microwave irradiation using 
Biotage Initiator 2.5 apparatus for 35 min at 120 °C. After cooling to room temperature, the reaction 
mixture was diluted with ether and CH2Cl2 and filtrate through a small pad of celite. The filtrate was 
washed with 0.1M HCl and extracted with CH2Cl2. The organic layer was washed with satd. aq. solution 
of NaHCO3 and water and dried over anh Na2SO4. After filtration, the solvent was removed under 
reduced pressure. The crude product was subjected to silica-gel flash chromatography, Biotage SP1, using 
hexane / EtOAc as eluent. The final product 50 was obtained as a pale yellow solid (30.4 mg, 41%). IR 
(ATR): 3392w, 2962w, 2835w, 2742w, 2156w, 1702m, 1598m, 1566w, 1491w, 1449w, 1415w, 1341w, 1308w, 
1250m, 1216w, 1169w, 1112w, 838m, 799m, 762w, 699w, 643w cm-1. 1H NMR (500 MHz, CDCl3, δ): 10.00 
(s, H-CO), 7.89, 7.76 (ABq, JAB = 8.2, 4H, H-C(2), H-C(3), H-C(5) and H-C(6)), 7.57, 7.49 (ABq, JAB = 8.4, 4H, 
H-C(2''), H-C(3''), H-C(5'') and H-C(6'')), 7.44, 7.34 (ABq, JAB = 3.8, 2H, H-C(3’) and H-C(4’)), 0.27 (s, 9H, 3 × 
Si-CH3). 13C NMR (125 MHz, CDCl3, δ): 191.40, 145.03, 142.33, 139.84, 135.21, 133.77, 132.63, 130.56, 126.18, 
125.75, 125.38, 124.94, 122.69, 104.74, 95.79. GC/MS (m/z (%)): 360.1 ([M+], 91); 345.1 (100). 
N1-(quinolin-4-yl)octane-1,8-diamine AQ10. 
The general procedure D was followed using 4-chloroquinoline (650 
mg, 4.0 mmol) and 1,8-diaminooctane (2.86 g, 19.8 mmol). The final 
product was obtained as a brown oil (701.9 mg, 65%). IR (ATR): 
3290m, 2928s, 2854m, 1653w, 1583s, 1544m, 1462m, 1440m, 1396w, 
1375w, 1342m, 1256w, 1127w, 882w, 809w, 767m cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.55 (d, J = 5.3, H-
C(2’)), 7.99 – 7.97 (m, H-C(8’)), 7.74 – 7.72 (m, H-C(5’)), 7.64 – 7.60 (m, H-C(7’)), 7.43 – 7.40 (m, H-C(6’)), 
6.42 (d, J = 5.4, H-C(3’)), 5.04 (bs, H-N), 3.33 – 3.29 (m, 2H, H-C(1)), 2.68 (t, 2H, J = 7.0, H-C(8)), 1.79 – 1.73 
(m, 2H, H-C(2)), 1.50 – 1.30 (m, 12H, 2H-N, 2H-C(3), 2H-C(4), 2H-C(5), 2H-C(6) and H-C(7)). 13C NMR 
(125 MHz, CDCl3, δ): 151.03, 149.64, 148.40, 129.93, 128.89, 124.48, 119.14, 118.66, 98.72, 43.19, 42.16, 33.71, 
29.30, 28.89, 27.06, 26.76. HRMS m/z 272.21141 corresponds to molecular formula C17H25N3H+ (error in 
ppm -2.62). 
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N-quinolin-4-yl-N'-[4-(5-{4-[(trimethylsilyl)ethynyl]phenyl}-2-thienyl)benzyl]octane-1,8-diamine (51). 
The general 
procedure A was 
followed using 50 
(44.6 mg, 0.124 
mmol), AQ10 (40.2 mg, 0.148 mmol), MeOH/CH2Cl2 (5.4 mL, 2:1, v/v), glac. AcOH (12 µL, 0.21 mmol) and 
NaBH4 (28 mg, 0.74 mmol). After working up the reaction in a manner provided in a general procedure 
A, the crude product was subjected to silica-gel column chromatography using EtOAc/MeOH as eluent 
and NH flash chromatography, Biotage SP1, using hexane/EtOAc and EtOAc/MeOH as eluent. The final 
product 51 was obtained as a pale yellow solid (19 mg, 25%). IR (ATR): 3244m, 3073m, 3025m, 2924s, 
2852m, 2156m, 1582s, 1544m, 1496m, 1454m, 1398m, 1376m, 1280w, 1248m, 1130w, 1109w, 1017w, 943w, 
863m, 841m, 802m, 760m, 664w cm-1. 1H NMR (500 MHz, CDCl3 + D2O, δ): 8.53 (d, J = 5.3, H-C(2)), 7.98 (d, 
J = 8.5, H-C(8)), 7.71 (d, J = 8.4, H-C(5)), 7.64 – 7.60 (m, H-C(7)), 7.58 – 7.54 (m, 4H, H-C(2’), H-C(6’), H-
C(2'') and H-C(6'')), 7.47 – 7.46 (m, 2H, H-C(3'') and H-C(5'')), 7.43 – 7.40 (m, H-C(6)), 7.34 – 7.33 (m, 2H, 
H-C(5’) and H-C(3’)), 7.29 – 7.26 (m, 2H, ovlp with solvent signal, H-ArS), 6.41 (d, J = 5.3, H-C(3)), 3.79 (s, 
2H, ArCH2-), 3.30 (t, J = 7.2, 2H, ArNHCH2-), 2.63 (t, J = 7.2, 2H, -CH2NHCH2CH2-), 1.78 – 1.72 (m, 2H, 
ArNHCH2CH2-), 1.54 – 1.43 (m, 4H, -CH2NHCH2CH2(CH2)3CH2-), 1.39 – 1.35 (m, 6H, -
CH2NHCH2CH2CH2CH2CH2-), 0.26 (s, 9H, 3 × Si-CH3). 13C NMR (125 MHz, CDCl3, δ): 151.03, 149.70, 
148.37, 144.19, 142.51, 140.20, 134.28, 132.84, 132.52, 129.96, 128.99, 128.73, 125.67, 125.14, 124.59, 124.57, 
123.96, 121.99, 119.14, 118.68, 104.93, 98.79, 95.31, 53.72, 49.42, 43.27, 30.09, 29.46, 29.33, 28.97, 27.28, 27.12. 
HRMS: m/z 616.31641 corresponds to molecular formula C39H45N3SSiH+ (error in ppm -1.96). 
N-{4-[5-(4-ethynylphenyl)-2-thienyl]benzyl}-N'-quinolin-4-yloctane-1,8-diamine (52). 
To a solution of 51 (16 mg, 
0.026 mmol) in a dry MeOH 
(0.5 mL), anh. K2CO3 was 
added. The reaction mixture 
was stirred at room temperature for 24h. The organic product was extracted using ethyl-acetate, 
combined organic layers were washed with satd. aqueous solution of NaHCO3 and dried over anh. 
NaSO4. After filtration, the crude product was subjected to NH flash chromatography, Biotage SP1, using 
CH2Cl2/MeOH as eluent. The final product 52 was obtained as a pale yellow solid (14 mg, 99%). M.p. = 
110 – 112 °C. IR (film): 3302s, 2928m, 2854m, 1583s, 1541m, 1496m, 1456m, 1397w, 1375w, 1342m, 1281w, 
1127w, 940w, 837m, 801s, 765m, 737m, 647m cm-1. 1H NMR (500 MHz, CDCl3, δ): 8,54 (d, J = 5.3, H-C(2)), 
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7.98 (dd, J1 = 8.4, J2 = 0.9, H-C(8), 7.72 – 7.71 (m, H-C(5)), 7.64 – 7.60 (m, H-C(7)), 7.59 – 7.56 (m, 4H, H-
C(2''), H-C(3''), H-C(5'') and H-C(6'')), 7.50 – 7.49 (m, 2H, H-C(3’) and H-C(5’)), 7.43 – 7.40 (m, H-C(6)), 7.34 
(d, J = 8.3, 2H, H-C(2’) and H-C(6’)), 7.31, 7.25 (ABq, JAB = 3.8, 2H, H-ArS), 6.41 (d, J = 5.4, H-C(3)), 5.00 (bs, 
H-N, exchangeable with D2O), 3.80 (s, 2H, ArCH2NH-), 3.32 – 3.28 (m, 2H, ArNHCH2-), 3.14 (s, HCC-Ar), 
2.65 – 2.62 (m, 2H, ArCH2NHCH2-), 1.92 (bs, H-N, exchangeable with D2O), 1.78 – 1.72 (m, 2H, 
ArNHCH2CH2-), 1.56 – 1.43 (m, 4H, ArNHCH2CH2CH2CH2CH2CH2CH2-), 1.40 – 1.34 (m, 6H, 
CH2NHCH2CH2CH2CH2CH2-). 13C NMR (125 MHz, CDCl3, δ): 150.93, 149.75, 148.26, 144.31, 142.34, 140.18, 
134.64, 132.80, 132.68, 129.86, 129.02, 128.74, 125.68, 125.26, 124.68, 124.60, 123.97, 120.93, 119.16, 118.66, 
98.77, 83.51, 78.09, 53.69, 49.39, 43.27, 30.05, 29.44, 29.31, 28.95, 27.26, 27.11. HRMS: m/z 544.27759 
corresponds to molecular formula C36H37N3SH+ (error in ppm -0.94). HPLC purity (λ = 330 nm): method 
A: RT 10.262, area 95.36%, method B: RT 11.233, area 95.16%. 
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In vitro antiplasmodial activity 
The Malaria SYBR Green I - Based Fluorescence (MSF) Assay is a microtiter plate drug sensitivity assay 
that uses the presence of malarial DNA as a measure of parasitic proliferation in the presence of 
antimalarial drugs or experimental compounds.  As the intercalation of SYBR Green I dye and its 
resulting fluorescence is relative to parasite growth, a test compound that inhibits the growth of the 
parasite will result in a lower fluorescence.  D6 (CDC/Sierra Leone), TM91C235 (WRAIR, Thailand), and 
W2 (CDC/Indochina III) laboratory strains of P. falciparum were used for each drug sensitivity 
assessment.  The parasite strains were maintained continuously in long-term cultures as previously 
described in Johnson et al [6].  Pre-dosed microtiter drug plates for use in the MSF assay were produced 
using sterile 384-well black optical bottom tissue culture plates containing quadruplicate 12 two-fold 
serial dilutions of each test compound suspended in dimethyl sulfoxide.  The final concentration range 
tested was 0.5 – 10000 ng/ml for all assays.  Predosed plates were stored at 4°C until used, not to exceed 
five days.  No difference was seen in drug sensitivity determinations between stored or fresh drug assay 
plates (data not shown).  A batch control plate using Chloroquine (Sigma-Aldrich Co., Catalog #C6628) at 
a final concentration of 2000 ng/ml was used to validate each assay run.  The Tecan Freedom Evo liquid 
handling system (Tecan US, Inc., Durham, NC) was used to produce all drug assay plates.  Based on 
modifications of previously described methods by Plouffe et al [7] and Johnson et al [6], P. falciparum 
strains in late-ring or early-trophozoite stages were cultured in the predosed 384-well microtiter drug 
assay plates in 38 µl culture volume per well at a starting parasitemia of 0.3% and a hematocrit of 2%.  
The cultures were then incubated at 37°C within a humidified atmosphere of 5% CO2, 5% O2 and 90% N2, 
for 72 hours.  Lysis buffer (38 µl per well), consisting of 20mM Tris HCl, 5mM EDTA, 1.6% Triton X, 
0.016% saponin, and SYBR green I dye at a 20x concentration (Invitrogen, Catalog #S-7567) was then 
added to the assay plates for a final SYBR Green concentration of 10x.  The Tecan Freedom Evo liquid 
handling system was used to dispense malaria cell culture and lysis buffer. The plates were then 
incubated in the dark at room temperature for 24 hours and examined for the relative fluorescence units 
(RFU) per well using the Tecan Genios Plus (Tecan US, Inc., Durham, NC). Each drug concentration was 
transformed into Log[X] and plotted against the RFU values.  The 50% inhibitory concentrations (IC50s) 
were then generated with GraphPad Prism (GraphPad Software Inc., SanDiego, CA) using the nonlinear 
regression (sigmoidal dose-response/variable slope) equation.    
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